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STATISTICAL METHODS FOR EVALUATING BIOMARKERS SUBJECT
TO DETECTION LIMIT
Yeonhee Kim, PhD
University of Pittsburgh, 2011
As a cost eective diagnostic tool, numerous candidate biomarkers have been emerged for
dierent diseases. The increasing eort of discovering informative biomarkers highlights
the need for valid statistical modeling and evaluation. Our focus is on the biomarker data
which are both measured repeatedly over time and censored by the sensitivity of given assay.
Inappropriate handling of these types of data can cause biased results, resulting in erroneous
medical decision.
In the rst topic, we extend the discriminant analysis to censored longitudinal biomarker
data based on linear mixed models and modied likelihood function. The performance of
biomarker is evaluated by area under the receiver operation characteristic (ROC) curve
(AUC). The simulation study shows that the proposed method improves both parameter
and AUC estimation over substitution methods when normality assumption is satised for
biomarker data. Our method is applied to the biomarker study for acute kidney injury
patients. In the second topic, we introduce a simple and practical evaluation method for
censored longitudinal biomarker data. A modication of the linear combination approach
by Su and Liu [1] enables us to calculate the optimum AUC as well as relative importance of
measurements from each time point. The simulation study demonstrates that the proposed
method performs well in a practical situation. The application to real-world data is provided.
In the third topic, we consider censored time-invariant biomarker data to discriminate time
to event or cumulative events by a particular time point. C-index and time dependent ROC
curve are often used to measure the discriminant potential of survival model. We extend
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these methods to censored biomarker data based on joint likelihood approach. Simulation
study shows that the proposed methods result in accurate discrimination measures. The
application to a biomarker study is provided.
Both early detection and accurate prediction of disease are important to manage serious
public health problems. Because many of diagnostic tests are based on biomarkers, discovery
of informative biomarker is one of the active research areas in public health. Our method-
ology is important for public health researchers to identify promising biomarkers when the
measurements are censored by detection limits.
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1.0 INTRODUCTION
Biomarkers are measurable factors that can be used as an indicator of disease or a progres-
sion of disease. For example, cholesterol level works as a risk predictor of vascular disease,
and serum creatinine is a surrogate for renal disease progression. Due to a biomarkers' cost-
eective benet for the diagnosis and prognosis of acute and chronic diseases, discovery of
a new biomarker is one of the active areas in medical research. Researchers have developed
several evaluation tools for biomarker discovery. Diagnostic measures quantify biomarker's
ability of discrimination. It focuses on whether the biomarker can separate patients into
event/non-event group. On the other hand, prognostic measures indicate biomarker's pre-
dictive capacity of disease occurrence. The risk can be expressed as a function of biomarker
through a statistical model such as logistic regression or Cox proportional hazard model.
Biomarker data are collected from many dierent procedures, designs and sampling
schemes. For instance, biomarkers can be collected only at one time point, or collected
repeatedly over several time points. Regardless of the data structure, it is tempting to use
only the most recent data in the analysis because of a complexity in handling longitudinal
data. Besides the high dimensionality of longitudinal data, analysis of biomarker data be-
comes more complicated if some measurements are censored. The censoring occurs due to
a limit of detection (LOD). In this case, only measurements which lie between lower and
upper detection limits are observable.
We encountered longitudinal censored data from two biomarker studies: The Genetic and
Inammatory Markers of Sepsis (GenIMS) study and the Biological Markers of Recovery for
the Kidney (BioMaRK) study. The GenIMS study is a multicenter, cohort study of 2320
patients with community acquired pneumonia (CAP) followed over time. The CAP is the
most common cause of sepsis that can lead to death. A set of biomarkers were measured
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daily for a week or longer during the hospitalization. One of the goals of this study was to
nd the relationship between pathways of biomarkers and the risk of sepsis and death. Be-
cause of the sensitivity of the assays used to measure the biomarkers, concentration of some
biomarkers was below the detectable limit, resulting in a portion of unquantiable data.
The BioMaRK study was conducted as a part of a large randomized clinical trial [2], and
enrolled patients who have a renal-replacement therapy for acute kidney injury. The acute
kidney injury is a clinically challenging problem for both physicians and patients. Although
it is directly related to the health care cost and well-being of patients, eective treatment
of acute kidney injury is still not available. Hence, many clinical studies were initiated to
explore informative biomarkers for the outcome of renal function. In BioMaRK study, multi-
ple plasma and urinary biomarkers are measured repeatedly, and the measurements of some
biomarkers are censored due to detection limits. In the previous analysis of longitudinal
data, it was common to analyze the biomarker at each time point separately. Censored
data were usually deleted or substituted by LOD or LOD/2 with the justication that it
is easy to implement and widely understood [3]. However, investigators are frequently in-
terested in longitudinal performance of biomarkers. Furthermore, disregarding the censored
data often causes signicant biases in the estimates of the xed eects and variance com-
ponents, inaccurate estimates of summary statistics, and inaccuracies in risk assessments
[4] [5]. The objectives of our research are (1) to develop a classication method for the
longitudinal biomarkers subject to left or right censoring due to lower or upper detection
limit, and (2) to evaluate the censored biomarker performance for both binary and survival
outcomes. The organization of the dissertation is as follows. In chapter 2, we review the
models for longitudinal data and existing methods for handling censored data. Underlying
theory on the classication method is introduced, followed by statistical evaluation tools for
binary and survival outcomes. Chapter 3 contains the classication methods for longitudinal
censored data. In chapter 4, we present how to incorporate the longitudinal biomarkers in
the ROC analysis for both censored and non-censored cases. In chapter 5, we change the
outcome of interest from binary data to survival data. With the baseline censored biomarker
measurements, we calculate the discrimination accuracy for survival outcome by modifying
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the original estimation methods for time dependent ROC and C-index. In chapter 6, we
close the dissertation with summary on the proposed methods and discussion about future
extensions.
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2.0 LITERATURE REVIEW
2.1 CLASSIFICATION METHODS
Linear discriminant analysis (LDA) and logistic regression are two standard statistical meth-
ods for classication. They are similar in terms of comparing the posterior probabilities that
a subject is from group k (Groupk) when deciding a group membership. Suppose biomarker
Y from Groupk is an n 1 vector of observations with mean k and covariance matrix k.
The k is the prior probability of a subject belonging to Groupk (k = 0, 1). LDA assumes
that biomarker data follow a normal distribution with common covariance matrix, 0 = 1
=. The probability density function of Y from Groupk is
fk(Y ) =
1
(2)n=2jj1=2 exp

 (Y   
k)t 1(Y   k)
2

:
Using the Bayes's rule, the posterior probability of Groupk is calculated as
Pr(GroupkjY ) = fk(Y )k
f0(Y )0 + f1(Y )1 :
Two posterior probabilities are compared in a log scale so that the log ratio of posterior
probabilities leads to an equation linear in Y [6]. We call it as a discriminant function of
LDA. Because when 0 = 1 = ,
log
Pr(Group1jY )
Pr(Group0jY ) = log
f1(Y )
f0(Y )
+ log
1
0
= log
1
0
  1
2
(1 + 0)t 1(1   0) + Y t 1(1   0):
(2.1)
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The assumption of LDA is generalized in quadratic discriminant analysis (QDA) by
allowing dierent covariance matrices between groups. If Y from Groupk is distributed
according to N(k, k), the quadratic discriminant function is
Y t
 
0
 1   1 1

Y
2
+ Y t
 
1
 11   0 10

+ log
1
0
  logj1j=j0j
2
  1
2
 
1t1
 11   0t0 10

:
While LDA has a linear discriminant boundary, the discriminant function of QDA has a
quadratic term of Y , leading to a quadratic boundary. Non-linear boundary for classication
works better especially in case of non-normal data and heterogeneous covariance matrix for
two groups.
More generally, likelihood ratio method has long been recognized as an optimal classi-
cation rule and it does not require assumptions such as normality or homogeneous covariance
matrix. Using the Bayes rule, it can be shown that the likelihood ratio rule is equivalent
to rules based on the posterior probability Pr(GroupkjY ). In this sense, the discriminant
analysis provides classication which achieves optimality [7].
The discriminant function is compared with a cuto point to determine a group member-
ship. A cuto point c is set by the decision theory. The most common goal in the decision
theory is to minimize the expected loss. Let L(Groupk; Groupj) be a loss function that
indicates the loss by misclassifying a subject in Groupk as in Groupj (j = 1    d). The
minimum expected loss can be written in a functional as
minc(Expected loss) = minc
"
dX
j=1
L(Groupk; Groupj)Pr(GroupjjY )
#
:
The loss function is chosen depending on the cost of a false positive and false negative.
In a logistic regression, log odds of a posterior probability is assumed to be linear in Y :
log
Pr(Group1jY )
Pr(Group0jY ) = 0 + 1Y: (2.2)
It follows from the equations (2.1) and (2.2) that
log
1
0
  1
2
(1 + 0)t 1(1   0) + Y t 1(1   0) = 0 + 1Y:
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The only dierence between LDA and logistic regression is a distributional assumption. LDA
assumes that the biomarker in each group follows a normal distribution with common co-
variance matrix. In contrast, logistic regression does not impose any restrictions on the
distribution. It is known that logistic regression is more exible and performs better when
the normal assumption is violated. However, LDA is shown to perform better and yield more
ecient estimates of parameters with smaller variance when the assumption is satised. In
addition, results from LDA are more stable when subjects are classied into more than two
groups [6].
Fisher's linear discriminant analysis
Fisher's discriminant analysis is closely linked to LDA. Fisher's discriminant analysis nds a
coecient  that can best discriminate the data in dierent classes. The principle of the best
discrimination is to maximize the ratio of between class variance to within class variance.
The objective function to maximize is expressed as
J() =
tSB
tSW
;
where
SB =
dX
k=1
k(
k   )(k   )t; SW =
dX
k=1
k
"
1
nk
X
y2Groupk
(Y   k)(Y   k)t
#
;
 is the grand mean, nk is the number of subjects in Groupk and  indicates a linear subspace
within which the projection of observations from dierent classes are best separated. When
there are two classes, the solution for  is S 1W (1   0) [8]. We can recognize that the
linear coecient of Y in the discriminant function (2.1) is exactly the same as Fisher's linear
discriminant coecient, given the fact that
Y t 1(1   0) = (1   0)t 1Y = f 1(1   0)gtY = fS 1W (1   0)gtY:
LDA projects biomarker measurements into the linear subspace generated by  1(1   0),
which is the Fisher's linear discriminant coecient, and clusters them into dierent groups
that are separated by a linear boundary based on the minimum expected loss.
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2.2 STATISTICAL METHODS FOR CENSORED DATA
When an instrument is not sensitive enough to measure very high or low values, only observ-
able values are reported for the analysis. Several parametric and non-parametric methods
such as deletion, substitution, imputation, and maximum likelihood method have been pro-
posed to resolve the problems.
Deletion means the elimination of all censored data. It reduces the sample size and could
produce a large bias. The missing pattern due to elimination is 'nonignorable missing' be-
cause the absence of data depends on detection limits. Alternative method is a substitution
of censored values by LOD, LOD/2 or LOD=
p
2 [9]. The substitution method is widely used
in practice due to its simplicity. However, the substitution still leads to a biased estimation
if the distribution of a biomarker beyond LOD is still informative. If the distributional as-
sumption is possible for measurement data, conditional expected value E(Y jY < LOD) can
be assigned to censored data, which is calculated based on the parameters of the distribution
and detection limit value [10]. Another, but similar method is single imputation method [11].
From the estimated distribution, it replaces censored data with randomly sampled values.
The single imputation method can make estimates minimally biased, but still produces too
narrow condence interval particularly when more than 30% observations are censored. The
major problem of single imputation is that the method ignores complexity of the model as
well as variability of the imputation process [12]. For left-censored data, one might think
that they are not important because the actual values must be extremely small. However,
censored data still have a large eect on the estimates of mean and variance, descriptive
statistics, regression coecient, its standard errors, and power of hypothesis tests, especially
when the proportion of censoring is not small [13].
To protect against above problems, multiple imputation (MI) method is suggested for
censored data [12] [14]. In MI method, maximum likelihood estimates are rst obtained for
parametric distribution using all available data. With the estimated parameters, censored
data are imputed by a sampling procedure. Because the imputed values are not real data, the
imputation process is usually repeated several times to create multiple complete data sets.
The analysis result from each dataset is combined later to account for variability. The MI
7
method provides accurate estimates and robust results even though the censoring proportion
is high [15]. Another promising statistical approach from methodological perspective is
a maximum likelihood estimation (MLE) method. It uses a modied likelihood function
that can incorporate the mechanism of censoring in parametric models [16]. The tobit
model, which uses a truncated normal distribution for censored data, is one of the widely
applied parametric models [17]. MLE method provides less biased estimates and increased
standard errors compared to the substitution method when data follow approximately normal
distribution [18] [15]. Although some drawbacks exist, for example, MLE works poor when
a sample size is small and outliers exist, this method is still preferred to others because
MLE itself has several desirable properties such as consistency, asymptotic unbiasedness,
and eciency. It is often considered the gold standard provided that the data are well
described by a (log)normal distribution [4] [19] [3] [20].
2.3 EVALUATION OF BIOMARKER
Biomarker's usefulness is often evaluated from either discrimination or risk prediction point
of view. Discrimination describes how well a model separates subjects into event and non-
event group. Risk prediction concerns a predictive capacity of a biomarker. The predictive
capacity is quantied by a risk distribution in the population [21]. According to this def-
inition, a biomarker is said to be useful if predicted risks have a wide distribution in the
population so that clinicians can easily divide patients into low and high risk group with
fewer subjects being left in the intermediate equivocal risk range. Discrimination and risk
prediction are originated from dierent perspectives. If the objective is a correct classi-
cation, discrimination approach is appropriate. If the clinical utility of a biomarker is of
interest, risk prediction approach is preferred. There is no gold standard for the evaluation
method. It is recommended to choose a proper method depending on the objective of the
study. [22]
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Table 1: Concept of sensitivity and specicity
Test negative (T=0) Test positive (T=1)
Non-disease (D=0) Pr(T = 0jD = 0) = TNF Pr(T = 1jD = 0) = FPF
Disease (D=1) Pr(T = 0jD = 1) = FNF Pr(T = 1jD = 1) = TPF
2.3.1 ROC curve
Discrimination performance is usually expressed through sensitivity and specicity. When
a test result is dichotomized (i.e. disease/non-disease, positive/negative), sensitivity and
specicity directly show a frequency of correct classication. Assuming that a positive test
result indicates the presence of a disease, sensitivity is dened as a probability of a positive
test result given a patient has a disease. Specicity is dened as a probability of a negative
test result given a patient doesn't have a disease. Alternatively, sensitivity can be expressed
as true positive fraction (TPF) or 1 - false negative fraction (FNF). Another expression of
specicity is true negative fraction (TNF) or 1 - false positive fraction (FPF) (Table 1).
Sometimes researchers want to know the averaged sensitivity over all specicity region to
compare overall performances. Especially when the outcome has ordinal or continuous scale,
the ROC curve is a useful tool for summarization. The ROC curve is a graph of sensitivity on
y-axis as a function of (1-specicity) on x-axis under series of cuto points. In Figure 1, the
larger the AUC, the better the biomarker discriminates between diseased and non-diseased
subjects. The perfect accuracy corresponds to AUC of 1, and the practical lower limit for
the AUC is 0.5, which can be achieved by a random chance.
Nonparametric ROC curve
Empirical ROC curve is estimated without any assumptions on the distribution of biomarker
data. Let Y0i(i = 1;    ; n0) and Y1j(j = 1;    ; n1) be continuous test results from patients
without and with a disease, respectively. Nonparametric ROC curve is a non-smooth step
9
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Figure 1: Biomarker a shows the perfect accuracy whereas d shows the worst accuracy
function that changes values at most n0 + n1 + 1 points. Two coordinates of each point is
dened by
1  Specificity = 1
n0
n0X
i=1
I(Y0i > c)
Sensitivity =
1
n1
n1X
j=1
I(Y1j > c):
The AUC is a summation of the areas under the trapezoids and it is also equivalent to
Mann-Whitney U-statistics. The nonparametric estimator of AUC is expressed by
dAUC = 1
n0n1
n1X
j=1
n0X
i=1
 (Y0i; Y1j);
where
 (Y0i; Y1i) =
8>>><>>>:
1 if Y1i > Y0i
1
2
if Y1i = Y0i
0 if Y1i < Y0i
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The trapezoidal method is easy to implement, but underestimates the area when the number
of distinct test values is small. There are dierent methods to derive the variance for AUC,
such as methods by Bamber [23], Hanley and McNeil [24] and DeLong et al. [25]. Dene
Y0-components V10 for i
th subject and Y1-components V01 for j
th subject as
V10(Y0i) =
1
n1
n1X
j=1
 (Y0i; Y1j); (i = 1;    ; n0)
V01(Y1j) =
1
n0
n0X
i=1
 (Y0i; Y1j); (j = 1;    ; n1):
DeLong et al. [25] proposed the variance estimator for nonparametric dAUC as
dV ar( dAUC) = 1
n0
S10 +
1
n1
S01;
where
S10 =
1
n0   1
n0X
i=1
(V10(Y0i)  dAUC)2
S01 =
1
n1   1
n1X
j=1
(V01(Y1j)  dAUC)2:
Parametric ROC curve
The binormal ROC model is often employed as a parametric method to obtain a smooth
ROC curve. The binormal ROC model postulates a pair of overlapping normal distribu-
tions to represent the distribution of two populations [26]. Suppose continuous test results
from non-diseased population Y0  N(0; 20), and from diseased population Y1  N(1; 21).
Under each cuto point c,
Sensitivity = Pr(Y1 > c) = 

1   c
1

1  Specificity = Pr(Y0 > c) = 

0   c
0

; (2.3)
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where  is a standard normal cumulative distribution function. It follows from the equation
(2.3) that
Sensitivity = 

1   0
1
+
0
1
  1(1  Specificity)

:
The ROC curve is entirely determined by two parameters u and v, where u = (1 - 0)/1
is the standardized dierence in the means of diseased and non-diseased population, and v
= 0/1 is the ratio of the standard deviations of two populations. The AUC is calculated
as
AUC = Pr(Y0 < Y1) = 
 
1   0p
20 + 
2
1
!
= 

up
1 + v2

:
By Taylor's expansion, the variance formula for the parametric estimator of AUC is
V ar( dAUC) = @AUC
@u
2
V ar(u^) +

@AUC
@v
2
V ar(v^) +

@AUC
@u

@AUC
@v

Cov(u^; v^):
Under the asymptotic normality, 100(1 - )% condence interval for AUC is given bydAUC  Z=2qdV ar( dAUC).
ROC curve for censored data
The parametric ROC curve has been extended to incorporate the censored measurements due
to detection limit. Perkins et al. [27] [28] developed the method to estimate AUC by obtain-
ing consistent estimates for 1, 0, 20 and 
2
1. Their AUC, 

1 0p
20+
2
1

, yields the similar
value to the AUC from completely observed data. Vexler et al. [29] developed the maximum
likelihood ratio test to compare AUCs from two biomarkers subject to LOD. Because two
biomarker measurements (for example, cholesterol and HDL-cholesterol) from one subject
can be correlated, they took both censoring and correlation into account. They employed
bivariate normal distribution and used a cumulative distribution function for censored data
conditioning on non-censored data.
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Figure 2: Biomarker 1 is more predictive than biomarker 2.
2.3.2 Predictiveness curve
Although ROC curve has been the most popular method for a biomarker evaluation, it
does not take a risk distribution into account. Suppose all diseased subjects have same risk
values of 0.52 and all non-diseased subjects have values of 0.51. In the ROC analysis, this
would result in a perfect discrimination. Such a weakness triggers researchers to evaluate
biomarkers from a dierent perspective. Huang et al. [21] published a predictiveness curve as
a graphical way to present a predicted risk. It is a plot of predicted risk R(v) against the vth
percentile of the biomarker, where R(v) = Pr[D = 1jY = F 1(v)] and F is the cumulative
distribution function of biomarker Y . Even though the original scales of the biomarkers
are not comparable because the measurement can be dierent, they are transformed to a
common scale in the predictiveness curve by using a percentile of the biomarker. It has been
pointed out in many papers that the biomarker with a strong predictive capacity has steeper
curves that corresponds to a wide variation in risk [21] [30] [31]. In Figure 2, the biomarker
1 is more predictive than the biomarker 2 because more subjects are in high or low end of
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the risk. For example, the subjects in the bottom 10% of the marker distribution have risks
in the range of (0.15, 0.30) according to biomarker 1, but in a much higher range (0.30,
0.40) according to biomarker 2. If the predictiveness curve is close to the horizontal line, the
biomarker is no more helpful for making a medical decision.
2.3.3 C-index
The C-index was proposed by Harrell et al. [32] as an overall measure of discrimination
accuracy for survival outcome. The concept of C-index was motivated by Kendall's  , a
nonparametric version of correlation. In their original paper, the C-index was applied not
only to survival data but also to binary data. They pointed out that the C-index for binary
outcome is equivalent to the AUC. The denition of AUC for binary outcome is the prob-
ability that the diseased subject has worse biomarker value than the non-diseased subject.
Changing the outcome from a binary to survival time, the C-index is dened as the prob-
ability that the patient with better biomarker value will have a longer survival time than
the patient with worse biomarker record, assuming that these two patients are selected at
random.
Suppose that (Zi, Ui, Wi, Yi) are the actual survival time, predicted survival time,
predicted probability of survival at time t, and time-invariant biomarker measurements for
ith subject (i = 1,   , N), respectively. Harrell et al. [33] expressed C-index as Pr(Ui <
UjjZi < Zj). In practice, it is hard to predict individual's survival time. It is noted that
the predicted probability of survival until any xed time point (Wi) can take place of the
predicted survival time(Ui), if two estimates have one-to-one correspondence. One advantage
in the application is that this relationship holds when the proportional hazard assumption
is satised. Under the proportional hazard model, S(tjYi) = (S0(t))tYi , where S(tjYi) is the
survival function given the biomarker value Yi, S0(t) is the baseline survival function and 
is a regression parameter, the Ui and Wi are exchangeable, because [34]
Wi < Wj () S(tjYi) < S(tjYj)()
Z 1
0
S(tjYi)dt <
Z 1
0
S(tjYj)dt()Z 1
0
t  f(tjYi)dt <
Z 1
0
t  f(tjYj)dt() Ui < Uj:
14
Therefore, Pr(Ui < UjjZi < Zj) = Pr(Wi < WjjZi < Zj) = Pr(Yi > YjjZi < Zj). The
C-index of 1 indicates that the model has a perfect discrimination power, whereas a value
of 0.5 corresponds to an uninformative model.
Nonparametric version of estimation is possible for the C-index. A pair of subjects is
said to be concordant if (Yi > Yj , Zi < Zj) or (Yi < Yj , Zi > Zj). In contrast, a pair
(Yi > Yj , Zi > Zj) or (Yi < Yj , Zi < Zj) is said to be discordant. It is noted that not
all pairs are usable to determine concordance and discordance. A pair is usable only when
one subject has an event before the other experiences an event or censored. For example,
we discard pairs if neither of subjects have events or two individuals have the same survival
time. Let R be a set of all usable pairs and Q be a total number of usable pairs in R. The
C-index is estimated by
C^ =
1
Q
X
(i;j)2R
cij;
where
cij =
8<: 1 if (Zi < Zj and Yi > Yj) or (Zi > Zj and Yi < Yj)0 if (Zi < Zj and Yi < Yj) or (Zi > Zj and Yi > Yj):
The original C-index is investigated further to overcome shortcomings. Yan and Greene [35]
found that the C-index depends on the number of tied pairs. Therefore, in the presence
of large proportion of tied pairs, they recommended to report both C-indices with and
without ties. Another modication is done by Uno et al. [36] for censored survival data. To
overcome the C-index's dependence on the underlying censoring distribution, they presented
the consistent estimates which is free of censoring by using an inverse probability weighting
technique. The condence interval for C^ is developed by Pencina and D'Agostino [34]. The
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100(1 - )% condence interval is C^  z=2
qdV ar(C^),
dV ar(C^) = 4
N(pc + pd)4
(p2dpcc   2pcpdpcd + p2cpdd);
pc =
1
N(N   1)
X
i
ci , pd =
1
N(N   1)
X
i
di
pcc =
1
N(N   1)(N   2)
X
i
ci(ci   1) , pdd = 1
N(N   1)(N   2)
X
i
di(di   1)
pcd =
1
N(N   1)(N   2)
X
i
cidi;
and ci is the number of concordant pairs, di is the number of disconcordant pairs with the i
th
subject in the sample, and z=2 is (1 - =2) percentile of the standard normal distribution.
2.3.4 Time dependent ROC analysis
When a biomarker is used for a diagnosis of disease that changes over time, the original
ROC analysis is no longer applicable. In the interval monitoring framework, DeLong et
al. [37] and Parker and DeLong [38] developed the new ROC methodology using parameter
estimates from discrete logistic regression. When continuous time to event data are available,
however, time dependent ROC analysis could be performed. The time dependent ROC was
introduced as an extension of the existing concept for sensitivity and specicity to survival
outcome. We assume that the higher biomarker values are more indicative of shorter survival
time. There are three dierent denitions of time dependent ROC.
A cumulative/dynamic time dependent ROC is used when the main question is whether
the biomarker can distinguish the patients who have experienced the event by time t and
who have not [39]. The cumulative case refers to the subject who has experienced the event
during the time interval (0, t], whereas the dynamic control refers to the subject with no
event by time t. With the cuto point of c, sensitivity and specicity are dened as
Sensitivity(t) = Pr(Y > cjZ  t)
Specificity(t) = Pr(Y  cjZ > t):
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The time dependent sensitivity and specicity are estimated using Kaplan-Meier estima-
tor based on the subset of Y  c or weighted Kaplan-Meier estimator based on nearest
neighbor kernel. The condence interval of time dependent ROC curve is calculated by
bootstrap method. This ROC method can be used clinically when the sensitivity of stan-
dard and new diagnostic measures are compared at certain time points to check whether
the new measure provides improved discrimination during the follow-up time. Later, the
cumulative/dynamic time dependent ROC is generalized to longitudinal biomarker [40] and
competing risk outcomes [41]. For the longitudinal biomarker, the question of interest is
how well a biomarker measured at a certain time point after the baseline can discriminate
diseased and non-diseased subjects in a subsequent time interval.
Alternative approach is an incident case and dynamic control time dependent ROC [42].
Under this denition, only subject who has an event at time t plays a role of case. The
dynamic control corresponds to the subject who is event free by time t. The incident/dynamic
time dependent sensitivity and specicity are dened as
Sensitivity(t) = Pr(Y > cjZ = t)
Specificity(t) = Pr(Y  cjZ > t):
The sensitivity can be estimated under proportional hazard model by computing the ex-
pected fraction of failures with a biomarker level greater than c. The specicity is estimated
by the empirical distribution function for biomarker among those who survive beyond t.
Bootstrap condence interval can be constructed for nonparametric time dependent ROC.
It is particularly useful when investigators want to display the incident discrimination ability
over time. It is interesting to know that the C-index is a weighted average of the area under
the incident/dynamic time dependent ROC [42].
The last version of time dependent ROC is dened with respect to incident case and
static control [43] [44]. Dening the case as the subject who experiences an event at time
t, the control is the subject who has not developed an event until a xed time point at t].
Unlike the other two denitions, the incident/static ROC curve changes over time depending
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only on the case group. The sensitivity and specicity is given as
Sensitivity(t) = Pr(Y > cjZ = t)
Specificity(t) = Pr(Y  cjZ > t]):
Zheng and Heagerty [45] estimated the incident/static time-dependent ROC curve by model-
ing the biomarker distribution conditional on the event status in a semiparametric way. The
ROC curve was expressed as a function of location and scale parameters from the biomarker
distribution. Incident/static ROC method is useful in a retrospective study especially when
the time to event is certain. As an alternative estimation method, the direct regression
approach of ROC curve was comprehensively reviewed and extended by Cai et al. [46] and
Pepe et al. [47]. Condence interval of the ROC curve can be based on bootstrap samples
or asymptotic property under certain regularity condition.
In this dissertation, we focus on the cumulative/dynamic time dependent ROC. One of
the questions addressed from our study is how well a biomarker can discriminate subjects
who had an event until time point t and those who remained event free up to t. To measure a
biomarker's discrimination potential for cumulative events by time t, which are time depen-
dent measures, cumulative/dynamic time dependent ROC analysis may be more appropriate
than others.
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3.0 DISCRIMINANT ANALYSIS FOR CENSORED LONGITUDINAL
BIOMARKER DATA
Discriminant analysis is commonly used to evaluate the ability of candidate biomarkers to
separate patients into pre-dened groups. Extension of discriminant analysis to longitudinal
data enables us to improve the classication accuracy based on biomarker proles rather
than on a single biomarker measurement. However, the biomarker measurement is often
limited by the sensitivity of the given assay, resulting in data that are censored either at
the lower or upper limit of detection. We develop a discriminant analysis method for cen-
sored longitudinal biomarker data based on mixed models. The biomarker performance is
assessed by AUC. Through the simulation study, we show that our method is better than
the simple substitution methods in terms of parameter estimation and evaluating biomarker
performance. We apply our method to a biomarker study aiming to identify biomarkers that
are predictive of the recovery from acute kidney injury for patients on renal replacement
therapy.
3.1 INTRODUCTION
As a noninvasive and cost-eective tool for diagnosis and prognosis of acute and chronic
diseases, biomarkers have received increasing attention for many decades. Two questions
raised commonly in the biomarker studies are (1) how to classify subjects into disease and
non-disease groups based on their measurements and (2) how to evaluate the clinical utility
of the biomarker. For classication and evaluation, several methods such as logistic re-
gression, discriminant analysis, and ROC curve have been widely applied for cross-sectional
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data. However, more and more studies highlight the importance of the temporal change
of biomarkers which can provide better understanding of the development of a disease [48].
Longitudinal biomarkers have been shown to lead to more accurate diagnosis than single
measurement. For example, de Leon et al. [49] stated that the diagnostic accuracy of mild
cognitive impairment is improved when longitudinal cerebrospinal uid marker is used. If
biomarkers are measured repeatedly over several time points, we may need specialized tech-
niques for capturing important time-related patterns in the repeated measurements. The
other concern in the biomarker study is the LOD. If an instrument is not sensitive enough
to detect very high and low concentrations, only measurements which lie between lower and
upper detection limits are observable. The results from inappropriate handling of these types
of data may mislead physicians in medical decision making.
Our work is motivated from the Biological Markers of Recovery for the Kidney (BioMaRK)
study. The recovery of a kidney function following the acute kidney injury (AKI) is an im-
portant determinant of morbidity and may have long-term implications for the health and
well-being of patients [50]. Hence, identifying informative biomarkers for predicting a 60-
day recovery is one of the primary goals of this study. There has been much eort in the
biomarker discovery related to AKI due to its unacceptably high mortality rates. Most stud-
ies focus on evaluating biomarker performance based on a single measurement. Even when
the biomarkers are measured over time, it is common to analyze the biomarker at each time
point separately or choose arbitrarily a summary measure such as change score or slope to
incorporate the longitudinal information. However, investigators are often more interested
in the overall performance of the longitudinal biomarker because biomarker evolution can
reveal better the biological process of a disease. In the BioMaRK study, multiple urinary
biomarkers are longitudinally measured, and the measurements of some biomarkers are cen-
sored due to detection limits. The objective of our research is to develop a classication
method for the longitudinal biomarkers subject to left or right censoring due to lower or
upper detection limit.
We develop the new classication and evaluation methods to take both censoring and
repeated measures into account. Discriminant analysis has been extended to the longitudinal
setting with a discriminant function estimated from mixed models [51] [52] [53] [54]. Further
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generalization to multivariate longitudinal data has been discussed by Marshall et al. [55]
using multivariate nonlinear mixed models. Kohlmann et al. [56] introduced the longitudinal
quadratic discriminant analysis and evaluated the classication performance using the ROC
curve and Brier score. If longitudinal data are censored due to a detection limit, however,
earlier proposed methods cannot produce an expected result. The problem of left-censoring
has been studied by many researchers [4] [19] [18]. They considered maximum likelihood
approaches to incorporate the censoring issue. As a related work to our objective from a
discriminant analysis perspective, Langdon et al. [57] discussed how to classify subjects
based on two censored variables. They estimated parameters by maximizing the marginal
likelihood function of bivariate normal distribution. These estimates were plugged into the
classier formed by Bayes optimum decision rule. We extend the idea of Langdon et al. [57]
to develop classication methods for longitudinal censored data, and show how AUC can be
constructed from discriminant analysis.
The organization of this chapter is as follows. In section 3.2, we introduce the underlying
theory of our discriminant analysis method. We describe how to classify subjects and how
to evaluate biomarker performance in the presence of censoring. In section 3.3, we compare
our method with simple substitution methods using simulated data. Finally, our method is
applied to the BioMaRK study to predict a patient's recovery status from AKI within 60
days after the enrollment.
3.2 METHOD
3.2.1 Linear mixed model for biomarker data
High dimensionality, serial correlations, unbalanced or unequally spaced repeated measures,
and missing data are typical issues that people encounter in the longitudinal analysis. Mixed
model is one of the popular approach to handle these problems [58]. The linear mixed model
captures the correlations between repeated measurements within a subject via random eects
(also called subject specic eects). Also, it can accommodate missing data when the missing
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and measurement processes are independent (missing completely at random; MCAR), or the
missing process depends only on the observed measurements (missing at random; MAR). Let
Yij be the biomarker measurement on the i
th individual at the jth time point, (i = 1,   , N ;
j = 1,   , ni). Thus, Yi = (Yi1;    ; Yini)t is an ni 1 vector of measurements corresponding
to the ith subject. The linear mixed model relating Yi to a set of covariates can be expressed
in the matrix notation as
Yi = Xi + Zii + ei;
where Xi is an ni p design matrix of xed eect,  is a p 1 population parameter vector,
and Zi is an niq design matrix of random eect. Random error ei and random eect i are
independent and normally distributed with ei  N(0; Ri) and i  N(0; Gi). Marginally, Yi
is normally distributed with mean Xi and covariance matrix i = ZiGiZ
t
i +Ri.
Parameters in the linear mixed model can be estimated from the likelihood function
formulated given the random eects. A likelihood function is simplied based on the mixed
model assumption that longitudinal observations are independent given the random eects.
To handle the censoring of biomarker measurements, we use the method similar to Lyles et
al. [19]. Suppose lower detection limit and upper detection limit are lo and up, respec-
tively. The likelihood function is constructed using the normal density function f(Yijji) for
observed measurements and the cumulative distribution function F (loji) or 1   F (upji)
for censored parts. Let  denote the vector of parameters in the covariance matrices. The
nal likelihood function for the covariance parameter vector  and coecient vector  is
given by
L(; ;Y ) =
NY
i=1
"Z
Rq
niY
j=1
ff(Yijji)I(dij=0)F (loji)I(dij=1) (1  F (upji))I(dij=2)gf(i)di
#
;
dij =
8>>><>>>:
0 if Yij is completely observed
1 if Yij is left censored at lo
2 if Yij is right censored at up;
I() is an indicator function:
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Once the likelihood function is dened depending on the censoring types, set of param-
eters  and  are estimated by maximizing the likelihood function. Because the likelihood
function includes cumulative distribution function to account for censored biomarker, we
apply SAS procedure Proc nlmixed to obtain the estimates. The Proc nlmixed proce-
dure allows us to specify the general form of distribution given the random eects. Integral
approximation is done by an adaptive Gaussian quadrature method and the likelihood is
maximized by dual quasi-Newton algorithm [59].
3.2.2 Discriminant analysis
We adopt the concept of discriminant analysis to construct the classier using longitudinal
censored biomarker measurements. Discriminant analysis arises from the desire to use an
optimal classication rule, and it is often based on the assumption of normal distribution
for two separate groups. Let fk(y) denote the normal density function (with mean 
k and
variance matrix k) of the longitudinal biomarker measurements for the subjects in group k
(k = 0, 1). For a subject with biomarker data Y , the posterior probability of assigning the
subject into group k is given by
Pr(GroupkjY ) = fk(Y )k
f0(Y )0 + f1(Y )1
;
where k is the prior probability that a subject belongs to group k without the knowledge
of Y . The ratio Pr(Group1jY )=Pr(Group0jY ) is then used as a discriminant function and
compared with a pre-dened cuto point to determine the group membership. Noting that
the corresponding log ratio
log
Pr(Group1jY )
Pr(Group0jY ) = log
f1(Y )
f0(Y )
+ log
1
0 ;
we refer to the rst term as a risk score S = log(f1(Y )=f0(Y )): When two groups have same
variance matrix (i.e. 0 = 1 = ), the risk score is simplied as
S =

Y   1
2
(1 + 0)
t
 1(1   0): (3.1)
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When variance matrices for two groups have dierent forms (i.e. 0 6= 1), the risk score is
S =
Y t
 
0
 1   1 1

Y
2
+ Y t
 
1
 11   0 10
  logj1j=j0j
2
  1
2
 
1t1
 11   0t0 10

:
The distributional parameters can be estimated from the mixed model. The estimation of S
for each individual depends on whether the subject has censored measurement or not. When
Y is completely observed, the risk score S can be directly calculated from equation (3.2.2)
using Y . If some components of Y are censored, we will substitute fk(Y ) in equation (3.2.2)
by f k (Y ), dened as
f k (Y ) =
Z
Rq
niY
j=1
ffk(Yijji)I(dij=0)Fk(loji)I(dij=1) (1  Fk(upji))I(dij=2)gfk(i)di
A new patient is classied by comparing his/her risk score to a pre-selected threshold. For
example, if we use the cuto point driven by the decision theory with Bayes 0-1 loss function,
the subject is classied into group 1 if S^ > 0, and classied into group 0, otherwise.
3.2.3 Evaluation of classication performance
AUC has long been dened for cross-sectional test results. Suppose variables T 0 and T 1
are the test results from normal and disease groups. The AUC is dened as Pr(T 1 > T 0),
that is, a probability that the test result for a randomly chosen individual with a disease is
more indicative of that disease than the test result from a normal subject. The test result
can be a continuous biomarker measurement. When the biomarker is measured over time,
the test result is a multivariate measure. To summarize the classication performance of a
multivariate test result to a univariate measure, we use the risk score S to serve as a test
result in the AUC calculation. In the following, we show how non-parametric and parametric
estimates of AUC are calculated based on the risk score S.
Nonparametric estimation of AUC
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With risk score S used as a test result, we may dene S1 and S0 as the risk scores for
a randomly chosen subject from group 1 and group 0 respectively. Suppose there are n0
controls and n1 cases in the data set. The sensitivity and specicity based on the estimated
risk score S^ can be formulated as
1  Specificity = 1
n0
n0X
i=1
I

S^0i > c

Sensitivity =
1
n1
n1X
j=1
I

S^1j > c

;
for a threshold c. The empirical ROC curve is obtained by connecting points [sensitivity(c),
1-specicity(c)]. The posterior probabilities Pr(GroupkjY ) have also been used to construct
the empirical ROC curve [52] [55] [56] in the longitudinal discriminant analysis. Note that
the posterior probability of belonging to group 1 is Pr(Group1jY ) = eS / (eS + 1), which is a
monotone transformation of S. Thus these two approaches lead to the same AUC given the
invariant property of ROC curve under monotone transformations. We can use trapezoids
method to estimate AUC and the method by DeLong et al. [25] for variance estimation. In
the presence of censoring, empirical AUC tends to produce lower values because it reects
the actual discrimination ability of incomplete information rather than a potential discrimi-
nation ability which could be achieved if LOD is eliminated.
Parametric estimation of AUC
In a special case when two groups have a common covariance matrix, the risk score has
a linear form in terms of Y (3.1). Then the AUC can be estimated based on the distribu-
tional assumption of the longitudinal biomarker measurements. A smooth ROC curve can
be obtained by
Sensitivity = 

t(1   0)p
t
+  1(1  Specificity)

; with  =  1(1   0);
25
and the AUC is dened as
AUC = Pr

S1 > S0

= Pr
"
Y 1   1
2
(1 + 0)
t
 1(1   0) >

Y 0   1
2
(1 + 0)
t
 1(1   0)
#
= Pr
h
 1(1   0)	t Y 1 >  1(1   0)	t Y 0i
= 
 
t(1   0)p
t(2)
!
; (3.2)
where  is a standard normal cumulative distribution function. The ROC curve and AUC
are estimated using ^0, ^1 and ^ from the linear mixed model. Because the AUC is entirely
determined by parameters 1, 0, and , it remains intact unless the estimates ^1, ^0, ^
are biased by the censored data. The standard error of AUC estimate can be calculated
following McClish's method [60].
3.3 SIMULATION STUDY
We conduct simulation study to evaluate the performance of the proposed discrimination
method. In practice, substitution methods are often used to handle the censored data due
to detection limits. Usually the censored observations are replaced by LOD or LOD/2. We
investigate how the discrimination measure AUC is aected by the censoring problem and
under what scenarios the naive substitution methods tend to introduce signicant bias. We
also examine the impact of misspecication of covariance structure on the discrimination
evaluation of longitudinal biomarker prole. In the simulation, we use the same set of sub-
jects in the estimation of parameters and AUC, which tends to make classication accuracy
overoptimistic. However, the bias of AUC due to this will be negligible for considered sample
size and number of parameters.
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We generate longitudinal biomarker measurement Yij for the subject i at time point Tij
from the mixed model:
Yij = '1 + '2Xi + '3Tij + '4(Xi  Tij) + ai + biTij + eij; (3.3)
where
eij  N(0; 2) and
0@ ai
bi
1A  N
240@ 0
0
1A ;
0@ 2a ab
ab 
2
b
1A35 :
Xi is a dichotomous variable, indicating the group membership (0 or 1) and Tij is a time
factor, indicating the follow up times of measurements (Tij = 1,2,3,4). Random intercept ai
and random slope bi are included in the model to reect the deviation of the subject specic
trajectory from the population trajectory. We assume that random eects are independent of
the random error. Note that the classication performance of a biomarker is determined by
the underlying separability in biomarker measurements between groups. The separability not
only depends on the regression coecient parameters which specify the dierence in mean,
but also the parameters in the covariance matrix. Larger variability in Y makes it more
dicult to divide the two groups. We x the regression parameters at '1 = 1.0, '2 = '3 =
0.5, '4 = -1.0, and the covariance parameters at 
2 = 1.0, ab = 0.0. This corresponds to the
scenario where the trajectories of two groups start at dierent baseline levels and increase over
time for one group and decrease for another group. Moreover, the variabilities of biomarker
measurements increase over time. To simulate biomarker data with dierent discrimination
ability, we change the variance in Y through the variance parameters of random eects, i.e.,
2a = 
2
b = 0.5, 1.0, and 2.0 with higher values representing poor separation between two
groups. We choose lower detection limit lo empirically so that the censoring rate of 20% and
40% can be achieved. We simulate 100 datasets, each including 200 subjects from individual
group.
The parameter estimates from the linear mixed model as well as parametric estimates
of AUCs, associated standard errors (se) and empirical 95% coverage probabilities (CP) are
summarized in Table 2. Comparing to the omniscient estimates based on the uncensored
complete data, the parameter estimates of the group ('2) and interaction ('4) eects are
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Table 2: Parametric estimation of AUC: Comparison of the discriminant ability between
proposed method (PM) and substitution methods ('2 = 0.5, '4 = -1.0, 
2 = 1.0)
Pr(censor) 2a; 
2
b Method '^2 '^4 ^
2 ^2a ^
2
b
^AUC(se) CP
0.2 2.0 Omni 0.488 -0.991 1.001 1.950 2.014 0.687(0.026) 0.960
LOD 0.140 -0.665 0.808 2.483 1.025 0.669(0.026) 0.890
LOD/2 0.129 -0.611 0.765 2.218 0.914 0.664(0.026) 0.860
PM 0.487 -0.991 1.003 1.927 2.012 0.688(0.026) 0.940
1.0 Omni 0.489 -0.994 1.001 0.963 1.008 0.740(0.024) 0.960
LOD 0.150 -0.673 0.782 1.266 0.525 0.709(0.025) 0.880
LOD/2 0.139 -0.628 0.736 1.147 0.481 0.717(0.025) 0.840
PM 0.487 -0.994 1.001 0.957 1.005 0.741(0.024) 0.950
0.5 Omni 0.489 -0.995 1.001 0.472 0.505 0.802(0.021) 0.970
LOD 0.168 -0.688 0.765 0.664 0.273 0.787(0.022) 0.900
LOD/2 0.158 -0.654 0.725 0.616 0.257 0.783(0.022) 0.850
PM 0.489 -0.996 1.002 0.469 0.504 0.803(0.021) 0.960
0.4 2.0 Omni 0.488 -0.991 1.001 1.950 2.014 0.687(0.026) 0.960
LOD 0.198 -0.548 0.567 1.242 0.791 0.660(0.026) 0.810
LOD/2 0.187 -0.556 0.589 1.351 0.803 0.661(0.026) 0.820
PM 0.470 -0.987 1.001 1.911 2.056 0.685(0.026) 0.910
1.0 Omni 0.489 -0.994 1.001 0.963 1.008 0.740(0.024) 0.960
LOD 0.201 -0.551 0.551 0.616 0.409 0.709(0.025) 0.690
LOD/2 0.181 -0.569 0.598 0.747 0.424 0.711(0.025) 0.740
PM 0.488 -0.996 1.001 0.966 1.000 0.742(0.024) 0.920
0.5 Omni 0.489 -0.995 1.001 0.472 0.505 0.802(0.021) 0.970
LOD 0.207 -0.555 0.537 0.304 0.216 0.767(0.023) 0.500
LOD/2 0.181 -0.587 0.611 0.431 0.228 0.773(0.023) 0.620
PM 0.492 -0.999 0.999 0.479 0.501 0.804(0.021) 0.920
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Table 3: Nonparametric estimation of AUC: Comparison of the discriminant ability between
proposed method (PM) and substitution methods ('2 = 0.5, 
2 = 1.0)
Pr(censor) 20; 
2
1 Method '^2 ^
2 ^20 ^
2
1
^AUC(se)
0.2 0.5,1.0 Omni 0.492 1.002 0.498 1.000 0.638(0.023)
LOD 0.438 0.763 0.273 0.711 0.636(0.023)
PM 0.492 1.001 0.496 1.000 0.639(0.023)
0.5,2.0 Omni 0.489 1.002 0.498 1.994 0.681(0.022)
LOD 0.514 0.779 0.292 1.354 0.673(0.022)
PM 0.485 0.994 0.483 1.999 0.677(0.022)
0.4 0.5,1.0 Omni 0.492 1.002 0.498 1.000 0.638(0.023)
LOD 0.357 0.569 0.112 0.456 0.630(0.023)
PM 0.488 1.001 0.490 1.000 0.634(0.023)
0.5,2.0 Omni 0.489 1.002 0.498 1.994 0.681(0.022)
LOD 0.464 0.589 0.117 0.896 0.662(0.022)
PM 0.501 0.993 0.469 1.998 0.670(0.022)
heavily biased when the censored observations are replaced by LOD or LOD/2. The pro-
posed method (PM) provides approximately unbiased estimates. As expected, the bias of
estimates continuously acts on the discriminant analysis and attenuates the AUC. Substi-
tution methods provide increasingly smaller AUCs with poor coverage probabilities as the
censoring proportion is increased. Our method, however, presents comparable AUCs to the
omniscient values, and the coverage probabilities are close to the nominal level of 0.95.
Generalizing the assumption on the variance matrix, we also estimate the AUC empiri-
cally as described in section 3.2.3. We make the variance matrices for two groups dierent
by allowing two random eects in the linear mixed model:
Yij = '1 + '2Xi + '3Tij + a0i + a1i + eij;
where eij  N(0; 2), a0i  N(0; 20) and a1i  N(0; 21). Two random intercepts a0i, a1i
and error eij are assumed to be independent each other. The parameters are xed at '1
= '3 = 1.0, '2 = 0.5, 
2 = 1.0, and (20, 
2
1) = (0.5, 1.0), (0.5, 2.0). Individual group
includes 300 subjects, each subject having 3 longitudinal time points. Table 3 summarizes
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Table 4: Performance measures and t statistics from dierent models
Pr(censor) 2a; 
2
b Model AIC BIC AUC(se)
0.2 2.0 True 0.687
RI 6604.35 6628.30 0.782(0.022)
RS 5686.15 5710.10 0.683(0.026)
RI + RS 5599.84 5631.77 0.688(0.026)
1.0 True 0.741
RI 5991.66 6015.61 0.844(0.019)
RS 5347.83 5371.77 0.732(0.024)
RI + RS 5312.57 5344.50 0.741(0.024)
0.5 True 0.803
RI 5492.32 5516.27 0.898(0.015)
RS 5083.71 5107.66 0.794(0.022)
RI + RS 5070.54 5102.47 0.803(0.021)
0.4 2.0 True 0.687
RI 5236.54 5260.49 0.772(0.023)
RS 4630.07 4654.02 0.689(0.026)
RI + RS 4568.18 4600.10 0.685(0.026)
1.0 True 0.741
RI 4836.06 4860.01 0.829(0.020)
RS 4401.94 4425.89 0.736(0.024)
RI + RS 4376.95 4408.88 0.742(0.024)
0.5 True 0.803
RI 4513.40 4537.35 0.884(0.016)
RS 4228.21 4252.16 0.797(0.022)
RI + RS 4219.54 4251.47 0.804(0.021)
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the result averaged over 100 datasets. Unlike the parametric estimate of AUC, the empirical
AUC estimate tends to be smaller than a potential AUC because the nonparametric ROC
curve is constructed based on the individual's score. If the individual has censored data
for at least one time point, his/her score is aected by incomplete measurements and its
original discriminative potential is reduced. In contrast, the parametric AUC is close to the
omniscient estimate which reects the potential discrimination ability, because it does not
depend on the individual's score, but depends on the mean and variance for each group.
To examine the impact of model misspecication on the biomarker evaluation, we gen-
erate the data from model (3.3), which is referred to as random intercept and slope (RI +
RS) model, but t the data with three dierent models: RI + RS model, random intercept
(RI) only model, and random slope (RS) only model. Table 4 shows the AUC estimates,
associated standard errors, and goodness-of-t statistics, Akaike information criterion (AIC)
and Bayesian information criterion (BIC), from three mixed models. Both RI only and RS
only models yield biased AUC estimates. The RI model overestimates the AUC, while the
RS model underestimates the AUC. Only the correct RI + RS model produces AUC estimate
close to the true one. In practice when we rarely know the true model, how can we believe
that we have a correct performance measure? It appears that the goodness of t statistics
such as AIC and BIC can be used as a general guideline. Overall, the model with better
goodness of t (smaller AIC and BIC) produces AUC estimate closer to the true one. Our
results are consistent with what was pointed out by Kohlmann et al. [56], incorrect model
specication may lead to spuriously better or worse performance measures.
3.4 APPLICATION TO BIOMARK STUDY
The Biological Markers of Recovery for the Kidney (BioMaRK) is an observational study
conducted as an ancillary study of the NIDDK-funded Acute Renal Failure Trial Network
(ATN) study. ATN study is a multicenter, prospective trial of two strategies for renal re-
placement therapy in critically ill patients with acute kidney injury (AKI) [61]. One of
the primary goals of the BioMaRK study is to nd biomarkers predictive for the recovery
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Figure 3: Boxplots of the log transformed NGAL and HA by recovery status
of renal function by 60 days after enrollment. The 'Recover' is dened as a survival with
dialysis-independent renal function, and 'No-recover' indicates a death or dependence on
dialysis. Serial measurements of plasma and urinary biomarkers are collected from the ATN
study participants who signed the consent form for biomarker determination. For illustration
purpose, we focus on the analysis of two urinary markers, Neutrophil Gelatinase-Associated
Lipocalin (NGAL) and Hyaluronic Acid (HA), that are obtained for 76 patients at day 1, 7,
and 14 after enrollment. Among 76 subjects, 38 (50%) recovered from AKI. NGAL is one
of the widely used urinary biomarkers for prediction of AKI. HA is a new biomarker that is
recently reported to correlate with both proteinuria and renal function in progressive renal
disease. NGAL measurements are censored by two upper detection limits at 500 and 10000
ng/mg.Cr. The proportions of censoring at day 1, 7 and 14 are 25.4%, 34.0%, and 27.3%,
respectively. HA level over 2029931.3 ng/mg.Cr is not measurable due to the detection
limit. Most of HA levels are within the detection limit and only 2.7% are censored at day 1.
We take a log transformation for NGAL and HA measurements to normalize the distribution.
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Figure 3 presents the group-level boxplots of NGAL and HA on a log scale over three time
points, where the censored observations are replaced with the detection limit. It appears
that both HA and NGAL levels go up a little at day 7 for the non-recovery group, but go
down over time for the recovery group. We consider several candidate models of dierent
covariance matrices (RI only, RS only, and RI + RS model) and dierent form of group-
specic trajectories. We choose the nal model with the smallest AIC and BIC as follows.
Yij = '1 + '2Recoveri + '3Timeij + '4Recoveri  Timeij + ai + eij
where
eij  N(0; 2) , ai  N(0; 2a)
Recoveri =
8<: 0 if subject i didn't recover within 60 days1 if subject i recovered within 60 days
The parameter estimates are shown in Table 5. The HA level correlates with the group
membership a little stronger than the NGAL does, as indicated by the magnitude and
signicance of the group eect and group by time interaction eect. It gives an evidence
that HA may have better discriminant ability than NGAL. The parametric AUC estimate
(standard error) for NGAL is 0.822 (0.047), and for HA is 0.853 (0.043) (Figure 4 left: the
black solid line and blue dotted line is for NGAL and HA, respectively). Substitution method
using LOD/2 produces AUC estimates of 0.612 (0.063) for NGAL and 0.841 (0.040) for
HA. We also perform cross sectional analysis to examine the discrimination ability of single
biomarker measurement. The AUCs for NGAL day 1, day 7, and day 14 measurements
are 0.662, 0.519, and 0.729 respectively. The corresponding AUCs for HA are 0.659, 0.563,
and 0.849. Clearly, the discrimination performance is signicantly improved by using the
biomarker prole rather than the measurement on a single day.
To assess the prediction capacity of the biomarkers, we take the risk distribution into
account using a predictiveness curve presented by Huang et al. [21]. Predictiveness curve is
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Table 5: Parameter estimates and standard errors from the linear mixed models for NGAL
and HA
NGAL HA
parameter estimate (se) P-value estimate (se) P-value
'1 6.960 (0.310) <0.0001 8.746 (0.321) <0.0001
'2 1.107 (0.440) 0.014 1.363 (0.460) 0.004
'3 0.064 (0.039) 0.109 0.071 (0.040) 0.083
'4 -0.189 (0.051) 0.001 -0.237 (0.054) <0.0001
2a 1.202 1.106
2 1.816 2.254
a plot of predicted risk against the percentile of the biomarker. It has been pointed out in
many papers that the biomarker with a strong predictive capacity has a steeper curve that
corresponds to a wide variation in risk [21] [30] [31]. If the predictiveness curve is close to the
horizontal line, the biomarker is no more helpful for making a medical decision. In Figure 4
(right: the black solid line and blue dotted line is for NGAL and HA, respectively), marker
HA is more predictive than marker NGAL because more subjects are classied into high
or low end of the risk. For example, the subjects in the bottom 10% of the risk score (S)
distribution have recovery probabilities in the range of (0.02, 0.19) according to marker HA,
but in a higher range (0.11, 0.23) according to marker NGAL. In the same way, the subjects
above 90th percentile of the distribution show higher recovery probabilities as predicted by
HA (0.91, 0.97) than NGAL (0.80, 0.92).
3.5 DISCUSSION
We propose a new discriminant analysis method to incorporate censored longitudinal biomarker
data. In the simulation study, we show that the substitution methods yield biased parameter
estimates and dierent discrimination results. The bias of our method is almost ignorable,
and the performance is satisfactory. The empirical AUC computed from the risk score
reects the actual discrimination power of longitudinal censored biomarkers. This AUC nat-
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Figure 4: ROC curve (left) and predictiveness curve (right) for NGAL and HA.
urally tends to be lower than the discrimination ability achievable with completely observed
biomarker measurements. It is also noted that the model selection is important to correctly
evaluate the biomarkers. Thus we recommend selecting the linear mixed model by comparing
t statistics. Our methodology can be widely applied to clinical decision-making when it is
necessary to handle below or above the threshold values, such as an investigation of health
eects from chronic low-level exposures [62].
The proposed classication method is based on the discriminant analysis that assumes
normal distribution for the longitudinal measurements. However, the biomarker data are
often highly skewed. Box-Cox transformation is an eective tool to make the distribution
of data close to normal. Several papers have discussed the Box-Cox transformation for cen-
sored data [63] [64] and for correlated data [65] [66]. Application of Box-Cox transformation
to censored multivariate data merits further research. We show discriminant analysis under
equality assumption of variance matrix for two groups and later generalize the assumption.
The generalized method is more applicable and exible, but increasing number of parame-
ters may cause a computational issue if the sample size is not large enough. Although we
introduce the discriminant analysis based on a single censored longitudinal biomarker, the
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extension to the multiple censored longitudinal biomarkers is possible because a complex
covariance structure can be used in the linear mixed model to account for the correlations
within subjects and between biomarkers.
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4.0 BEST LINEAR COMBINATION FOR LONGITUDINAL BIOMARKER
DATA
The diagnostic performance of a biomarker is commonly assessed by AUC. Estimation of
AUC is often complicated if biomarkers are collected over time, and even censored by the
sensitivity limitation of a given assay. For a practical biomarker evaluation, we extend the
linear combination method by Su and Liu [1] to censored longitudinal biomarker data. The
combination coecient derived from this method enables us to calculate maximum AUC
that can be obtained from fully observed data. Moreover, it can inform investigators which
time point is more important in making a medical decision. Simulation studies demonstrate
that the proposed method performs better than LOD/2 substitution method. Application
is presented for the GenIMS study to evaluate inammatory and coagulation biomarkers.
4.1 INTRODUCTION
Biomarkers are biochemical, genetic and molecular factors which can monitor biological and
pathological processes in human body. Because biomarkers are measurable before a disease
is clinically detected, they can help to make an important decision and reduce medical costs.
Scientists have made a big eort to develop new biomarkers for several indications such
as cancer and Alzheimer's disease. One of the important processes in biomarker research
is a performance evaluation. In many cases, ROC analysis is used to measure diagnostic
accuracy of a biomarker. As a summary measure of the ROC curve, AUC for a single
time point measurement has well been developed in both parametric and non-parametric
ways. For the evaluation of repeated measures, researchers have tried to use conditional
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probability and posterior probability calculated from Bayesian model or latent class model
[67] [68] [44] [69]. However, some methods are only applicable for specic conditions and any
standard approaches for longitudinal data have not emerged yet. One way to incorporate high
dimensional data is to use a linear combination so that we can use the original denition
of ROC curve. Researchers frequently would like to discover a biomarker which provides
higher AUC. With the investigators' goal of biomarker discovery in mind, an interesting
question at this point is how to condense longitudinal measurements and maximize AUC at
the same time. Besides the high dimension problem, researchers face another obstacle when
biomarkers are subject to detection limit. It is clear that results are biased if censoring is
not appropriately handled. Our goal is to nd a linear combination coecient for each time
point to produce the best AUC.
The idea of our method is based on the linear combination of multiple markers to nd an
ideal biomarker which has high sensitivity and specicity. The linear combination methods
were explored by researchers to maximize the sensitivity over the entire specicity range
[1] [70], over a range of high specicity [71] and at a xed specicity [72]. Whereas many
approaches are based on the distributional assumption, Pepe and Thompson [73] proposed
the distribution free approach to optimize AUC. However, all of these methods are only
applicable for fully observed data. For censored measurements due to LOD, a parametric
ROC method was investigated by Perkins et al. [27] [28]. They calculated AUC formulated
by parameters estimated from the modied likelihood function for the censored observations.
In the following sections, we present the formula for the best linear combination coecient
in terms of parameters of binormal distribution. We show how to estimate the parameters
from the linear mixed model for both biomarkers with and without LOD. Our method is
applied to the Genetic and Inammatory Markers of Sepsis (GenIMS) study examining
biomarker's discrimination power for the 90-day mortality for patients with community-
acquired pneumonia.
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4.2 METHOD
4.2.1 Best linear combination of longitudinal biomarker data
If biomarker concentrations are measured over time from the same individual, multiple
within-person level data are collected. Suppose the biomarker Y 0 from non-disease group
with n0 subjects and Y
1 from disease group with n1 subjects are expanded to p-dimensional
vectors. Assume Y 0 = (y01;    ; y0p)t MVNp(0;0) and Y 1 = (y11;    ; y1p)t MVNp(1;1),
where 1 and 0 are p  p positive denite matrices. With a linear combination coe-
cient  = (1;    ; n), we can make one-dimensional scores tY 0  N(t0; t0) and
tY 1  N(t1; t1). Now, the condensed measures tY 0 and tY 1 take a role of con-
tinuous test results in ROC analysis. The AUC is calculated based on the distributional
assumption :
AUC = Pr(tY 0 < tY 1) = 
 
t(1   0)p
t(0 + 1)
!
;
where  is standard normal cumulative distribution function. Our objective is to nd the
combination coecient  which maximizes the AUC. Since  is a strictly increasing function,
the maximization of AUC is equivalent to
max


t(1   0)(1   0)t
t(0 + 1)

: (4.1)
The combination coecient which maximizes (4.1) is an eigenvector of (0 + 1)
 1(1  
0)(1   0)t. What we actually care about  is only a direction, not a magnitude. For ex-
ample, =(1, 2, 3) gives the same AUC with =(2, 4, 6). In other words, AUC is maximized
when  is proportional to (0+1)
 1(1 0). This is the same result given by Su and Liu
[1] and Liu et al. [71].
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4.2.2 AUC estimation for the best linear combination
Based on the best linear combination coecient, we can obtain a smooth ROC curve, that
is,
Sensitivity = 

t(1   0) +  1(1  Specificity)pt0p
t1

;
where  = (0+1)
 1(1 0). The corresponding point estimate of the optimum AUC is,
dAUCopt =  u^p
1 + v^2

; where u =
t(1   0)p
t1
; v =
p
t0p
t1 :
(4.2)
To estimate parameters 0, 1, 0 and 1, we t the linear mixed model accounting for
correlations between repeated measures. Suppose the subject i (i = 1,   , N) has p 1
vector of longitudinal biomarker measurements Yi = (Yi1;    ; Yip)t. The linear mixed model
we consider is
Yi = Xi + Zii + ei;
where Xi is an p r matrix of xed eect,  is a r 1 parameter vector, and Zi is an p q
matrix of random eect. Random error ei and random eect i are independent and normally
distributed. If a biomarker measurement is not censored due to LOD, its contribution to
the likelihood function is through the normal density function f(Yijji). Otherwise, the
cumulative distribution function F (loji) or 1 F (upji) are used for left or right censored
parts, where lo and up are lower and upper detection limit, respectively. The likelihood
function for the covariance parameter vector  and coecient parameter vector  is given by
L(; ;Y ) =
NY
i=1
"Z
Rq
pY
j=1
ff(Yijji)I(dij=0)F (loji)I(dij=1) (1  F (upji))I(dij=2)gf(i)di
#
;
dij =
8>>><>>>:
0 if Yij is completely observed
1 if Yij is left censored at lo
2 if Yij is right censored at up;
I() is an indicator function:
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The condence interval for AUC is constructed using asymptotic normality property of
maximum likelihood estimate. The 100(1 - )% two-sided condence interval is dAUC 
z=2
qdV ar( dAUC). The variance of dAUC is estimated by [60]
dV ar( dAUC) =  d@AUC
@
!2 dV ar(^) + d@AUC
@20
!2 dV ar(^20) +
 d@AUC
@21
!2 dV ar(^21);
where  = t1   t0, 2k = tk (k = 0, 1), N = n0 + n1 and
d@AUC
@
=
e u^
2=(2+2v^2)q
2(1 + v^2)^21d@AUC
@20
=   u^v^e
 u^2=(2+2v^2)
2^0^1
p
2(1 + v^2)3d@AUC
@21
=  

u^
2^1
 d@AUC
@
!
  v^2
 d@AUC
@20
!
dV ar(^) = ^21
n0
+
^20
n1dV ar(^20) = 2^04n0   1dV ar(^21) = 2^14n1   1 :
In practice, the value of AUC is bounded by 0.5 and 1.0. If a true optimum AUC ap-
proaches 0.5 or 1.0, the distribution of estimated AUC becomes skewed, especially under a
small sample size. It is well known that Fisher's Z-transformation improves the behavior
of condence intervals when assessed by coverage rate. Even though the transformed AUC
does not strictly follow normal distribution, it tends to become normal rapidly with a small
increase of a sample size. The 100(1 - )% condence interval for Z-transformed AUCz isdAUCz  z=2qdV ar( dAUCz), where
AUCz = ln

1 + AUC
1  AUC

, V ar( dAUCz) = 4
(1  AUC2)2V ar(
dAUC);
and z=2 is (1 - =2) percentile of the standard normal distribution. The back transformation
(eAUCz 1)=(eAUCz+1) enables us to construct the condence interval for AUC in the original
scale [70] [60].
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We can notice that the AUC evaluating the performance of linear discriminant analy-
sis for longitudinal biomarker data is equivalent to the optimum AUC derived from linear
combination coecient under a certain condition. Suppose the covariance matrices for two
groups are same, i.e. 0 = 1 = . In section 3.2.3, we have shown that AUC from the
linear discriminant analysis is
Pr
h
 1(1   0)	t Y 1 >  1(1   0)	t Y 0i : (4.3)
Notice that the linear combination coecient  is proportional to  1(1   0). We can
rewrite (4.3) in terms of  as Pr [tY 1 > tY 0] = 

t(1 0)p
t(2)

, which has the same form as
that of the maximum AUC (4.2). Because this AUC depends only on the mean and variance
for each group, it remains intact for the censored biomarkers as long as the parameter
estimates are consistent.
4.3 SIMULATION STUDY
The linear combination coecient and the corresponding AUC depend on 0, 1, 0 and
1. When biomarkers are subject to LOD, conventional approach (so called substitution
method) have been widely used, which substitutes censored data to LOD or LOD/2 level.
However, we recommend to estimate parameters using the modied likelihood function. In
this simulation study, we compare the performance of our method and substitution method
by calculating the bias, standard error and coverage probability.
We simulate longitudinal biomarker data from two dierent random coecient models to
alter the covariance matrix. The data for the rst simulation are generated from the random
intercept model,
Yij = '1 + '2Xi + '3Tij + '4Xi  Tij + ai + eij; where eij  N(0; 2) and ai  N(0; 2a);
where Xi is the categorical variable of group membership (0 or 1) and Tij is follow up time
point (Tij = 1,2,3,4). The correlation between two measurements is  = 
2
a=(
2 + 2a). The
parameters are xed at '1 = 1.0, '2 = 0.9, '3 = 0.1, '4 = -0.2, 
2 = 1.0. The 2a are
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Table 6: Optimum AUC for the best linear combination of longitudinal biomarker measure-
ments that are generated from the random intercept model.
Pr(censor)  AUCtrue AUCopt SE Std CP Coecient
Proposed method
0.1 0.2 0.695 0.693 0.016 0.016 0.950 (0.25, 0.15, 0.05, -0.05)
0.5 0.657 0.656 0.017 0.017 0.935 (0.19, 0.09, -0.01, -0.11)
0.8 0.635 0.633 0.017 0.017 0.940 (0.16, 0.06, -0.04, -0.14)
0.2 0.2 0.695 0.693 0.016 0.016 0.930 (0.25, 0.15, 0.05, -0.05)
0.5 0.657 0.656 0.017 0.017 0.930 (0.19, 0.09, -0.01, -0.11)
0.8 0.635 0.634 0.017 0.017 0.945 (0.16, 0.06, -0.04, -0.14)
0.3 0.2 0.695 0.693 0.016 0.016 0.945 (0.25, 0.15, 0.05, -0.05)
0.5 0.657 0.656 0.017 0.017 0.935 (0.19, 0.09, -0.01, -0.11)
0.8 0.635 0.634 0.017 0.018 0.935 (0.16, 0.06, -0.04, -0.14)
0.4 0.2 0.695 0.693 0.016 0.017 0.940 (0.25, 0.15, 0.05, -0.05)
0.5 0.657 0.656 0.017 0.018 0.910 (0.19, 0.09, -0.01, -0.11)
0.8 0.635 0.634 0.017 0.019 0.890 (0.16, 0.06, -0.04, -0.14)
LOD/2
0.1 0.2 0.695 0.691 0.017 0.016 0.970 (0.27, 0.16, 0.06, -0.05)
0.5 0.657 0.652 0.017 0.016 0.950 (0.20, 0.10, -0.01, -0.11)
0.8 0.635 0.626 0.016 0.017 0.895 (0.16, 0.06, -0.04, -0.14)
0.2 0.2 0.695 0.689 0.017 0.016 0.940 (0.27, 0.16, 0.06, -0.05)
0.5 0.657 0.650 0.017 0.017 0.930 (0.21, 0.10, -0.01,-0.11)
0.8 0.635 0.623 0.015 0.017 0.845 (0.17, 0.07, -0.04,-0.14)
0.3 0.2 0.695 0.687 0.017 0.016 0.930 (0.27, 0.17, 0.06, -0.05)
0.5 0.657 0.648 0.016 0.016 0.910 (0.21, 0.10, -0.01,-0.11)
0.8 0.635 0.620 0.015 0.017 0.795 (0.17, 0.07, -0.04,-0.14)
0.4 0.2 0.695 0.683 0.016 0.016 0.890 (0.27, 0.17, 0.06, -0.04)
0.5 0.657 0.644 0.016 0.017 0.865 (0.21, 0.10, -0.04,-0.11)
0.8 0.635 0.616 0.014 0.017 0.725 (0.17, 0.07, -0.04,-0.14)
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varied so that  attains the value 0.2, 0.5 and 0.8. We generate 200 datasets, each having
500 diseased subjects and 500 normal subjects. A subject is assumed to have left censored
longitudinal biomarker measurements with censoring rates from 10% to 40%.
Table 6 summarizes the estimation results of optimum AUC (AUCopt) averaged over 200
datasets from the proposed method and LOD/2 substitution. The AUCtrue is calculated
using the true parameter values from which the data are generated. The SE indicates the
average of the estimated standard error. As an empirical standard error (Std), the standard
deviation of dAUCopt, is presented. The estimated optimum AUC from our method is very
close to the true AUC, and the standard error is comparable to the empirical standard error.
Up to the censoring proportion of 30%, empirical coverage probabilities (CP) are near to
0.95. The bias of AUC from the LOD/2 method gets larger with the increase of censoring
proportion and the coverage probabilities are generally worse than the proposed method.
Irrespective of the methods, the measurement at the rst time point has the highest weight
in the combination. This is not surprising because the trajectory pattern we simulated for the
two groups starts far apart each other and becomes narrower in the later time points. Besides,
the correlation between two consecutive measurements are same over time. Accordingly, the
contribution of biomarkers at the rst time point to the discrimination ability is the most
important.
In the second simulation, we simulate the data from the random intercept and slope
model,
Yij = '1 + '2Xi + '3Tij + ai + biTij + eij;
where eij  N(0; 2) and
0@ ai
bi
1A  N
240@ 0
0
1A ;
0@ 2a !ab
!ab 
2
b
1A35
:
In this model, correlations between two measurements are not xed, but dierent depending
on the time points. The covariance parameters 2a and 
2
b are set to 1.0 with other coecient
parameters being remained same as before. We change the correlation between the random
intercept and random slope ! from -0.8 to 0.8. Total 100 datasets are generated with 200
subjects in each group.
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Table 7: Optimum AUC for the best linear combination of longitudinal biomarker measure-
ments that are generated from the random intercept and slope model.
Pr(censor) ! AUCtrue AUCopt SE Std CP Coecient
Proposed method
0.1 -0.8 0.811 0.810 0.021 0.020 0.960 (0.41, 0.24, 0.06,-0.11)
0.0 0.728 0.728 0.024 0.022 0.950 (0.25, 0.13, 0.01,-0.11)
0.8 0.723 0.723 0.025 0.023 0.950 (0.29, 0.14, 0.00,-0.16)
0.2 -0.8 0.811 0.810 0.021 0.020 0.950 (0.41, 0.24, 0.06,-0.11)
0.0 0.728 0.729 0.024 0.023 0.970 (0.25, 0.13, 0.01,-0.11)
0.8 0.723 0.722 0.025 0.024 0.930 (0.29, 0.14, 0.00,-0.16)
0.3 -0.8 0.811 0.810 0.021 0.022 0.950 (0.41, 0.24, 0.06,-0.11)
0.0 0.728 0.728 0.024 0.023 0.970 (0.25, 0.13, 0.01,-0.11)
0.8 0.723 0.724 0.025 0.025 0.930 (0.29, 0.14,-0.01,-0.16)
0.4 -0.8 0.811 0.810 0.021 0.023 0.920 (0.41, 0.24, 0.07,-0.11)
0.0 0.728 0.728 0.024 0.026 0.940 (0.25, 0.13, 0.01,-0.11)
0.8 0.723 0.723 0.025 0.026 0.810 (0.29, 0.14,-0.01,-0.16)
LOD/2
0.1 -0.8 0.811 0.808 0.023 0.020 0.980 (0.37, 0.22, 0.06,-0.10)
0.0 0.728 0.728 0.028 0.023 1.000 (0.25, 0.13, 0.01,-0.11)
0.8 0.723 0.723 0.026 0.023 0.970 (0.29, 0.14,-0.01,-0.16)
0.2 -0.8 0.811 0.805 0.023 0.021 0.980 (0.30, 0.18, 0.05,-0.07)
0.0 0.728 0.721 0.030 0.024 0.980 (0.18, 0.09, 0.01,-0.08)
0.8 0.723 0.720 0.028 0.025 0.980 (0.27, 0.13,-0.01,-0.16)
0.3 -0.8 0.811 0.800 0.023 0.024 0.950 (0.25, 0.15, 0.05,-0.05)
0.0 0.728 0.721 0.030 0.024 0.980 (0.18, 0.09, 0.01,-0.08)
0.8 0.723 0.717 0.029 0.026 0.990 (0.23, 0.11,-0.01,-0.13)
0.4 -0.8 0.811 0.792 0.024 0.025 0.860 (0.20, 0.12, 0.04,-0.04)
0.0 0.728 0.713 0.031 0.026 0.950 (0.14, 0.07, 0.01,-0.06)
0.8 0.723 0.706 0.031 0.028 0.930 (0.17, 0.08,-0.01,-0.10)
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From the estimates of AUC, SE, and coverage probability in Table 7, we observe similar
results as we see for the mixed model with random intercept only. We can notice that the
linear combination coecients are not the same across dierent time points. The highest
and lowest absolute weights are assigned to the measurements from the rst and third time
points, respectively.
4.4 APPLICATION TO GENIMS STUDY
The Genetic and Inammatory Markers of Sepsis (GenIMS) study is a multicenter cohort
study of patients admitted to the emergency department with community acquired pneumo-
nia (CAP) between 2001 and 2003. The patients with CAP often experience severe sepsis
and infection related death, which costs $8.4 billion each year in the United States [74] [75].
Because these patients are reported to exhibit abnormal levels in biomarkers of inammation
and coagulation, further investigation in the biomarkers helps physicians to eciently man-
age CAP. The study enrolled 2320 patients and their biomarker levels were measured daily
during the rst seven days of hospitalization. The secondary objective of the study is to
identify biomarkers which predict patient's death by 90 days after hospitalization. We select
the pro-inammatory marker, interleukin-6 (IL-6) and the coagulation marker, D-dimer for
illustration. All biomarker measurements are transformed in a log scale to normalize the
distribution. The IL-6 has two lower detection limits at 2 pg/mL and 5 pg/mL. Censoring
proportions from day 1 to day 7 are 15.1%, 22.3%, 29.6%, 33.2%, 34.4%, 35.1%, and 34.2%.
Boxplots are presented in Figure 5 to show a group-specic trajectory. Although the box-
plots overlap between survival and death groups, IL-6 prole for the death group is higher
than that for the survival group. In both groups, IL-6 levels fall rapidly from day 1 to day
2, but drop slowly after day 3. Based on this prole, we include the variable 'Day after
hospitalization' as a reciprocal form. The estimated linear mixed model for log(IL-6) is
Yij = 1:463 + 1:104Xi + 2:139Tij + ai + biTij + eij;
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Figure 5: Boxplots for log transformed IL-6 and D-dimer by survival and mortality groups
where
eij  N(0; 0:551) and
0@ ai
bi
1A  N
240@ 0
0
1A ;
0@ 2:127  1:389
 1:389 5:031
1A35
Xi =
8<: 0 if subject i was not dead at 90 days after hospitalization1 if subject i was dead at 90 days after hospitalization
Tij =
1
Day after hospitalizationij
The mean vectors and covariance matrices for the survival and death groups are calculated
from the parameter estimates of the linear mixed model. The best linear combination coe-
cient for each time point is (0.016, 0.038, 0.045, 0.048, 0.050, 0.052, 0.053) showing that the
most recent measurement has the highest weight. The optimum AUC and 95% condence
interval for IL-6 are 0.718 (0.683, 0.750). Next, the lower detection limit for D-dimer is 110
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ng/mL and its censoring proportions are lower than IL-6 with 5.3%, 4.4%, 5.0%, 5.4%, 4.5%,
3.7%, and 4.0% over 7 days. Logarithm of D-dimer level for death group is a bit higher than
that of the survival group (Figure 5). The estimated linear mixed model for log(D-dimer) is
Yij = 6:215 + 0:729Xi + 0:021Tij + ai + biTij + eij
eij  N(0; 0:113) and
0@ ai
bi
1A  N
240@ 0
0
1A ;
0@ 1:063  0:061
 0:061 0:023
1A35
Xi =
8<: 0 if subject i was not dead at 90 days after hospitalization1 if subject i was dead at 90 days after hospitalization
Tij = Day after hospitalizationij
The linear combination coecient for each time point is (0.144, 0.070, 0.045, 0.033, 0.026,
0.021, 0.017). Contrary to the IL-6, the weights of the measurements for D-dimer decrease
over time. The optimum AUC for D-dimer is 0.695 (0.641, 0.741), which is smaller than the
AUC for IL-6.
4.5 DISCUSSION
High dimensionality and censoring issue are often a problem in the evaluation of biomarkers.
Motivated by the GenIMS study, we propose the method to nd the best linear combination
coecient for longitudinal biomarker measurements. By combining data from multiple time
points, we can reduce the time dimension of longitudinal data into one and capture dierent
evolution patterns. The combination coecient enables us to evaluate biomarker's maximum
classication power via AUC. Investigators can also predict the relative importance of each
time point to the discrimination ability. The method is applicable for both censored and non-
censored measurements. It is noted that the AUC calculated from the linear discriminant
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analysis is mathematically equal to the optimum AUC from the best linear combination
coecient. One of the limitations of our method is that it only considers the group level
parameters such as mean and variance for event and non-event groups, it's impossible to
know individual's classication result based on each subject's biomarker records. However,
the method is practically useful in terms of short computational time to provide a summary
statistic for biomarker's discrimination ability, especially when the biomarker is repeatedly
measured over several time points and censored due to LOD.
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5.0 DISCRIMINATION MEASURE OF CENSORED BIOMARKER FOR
SURVIVAL OUTCOME
Censoring due to a detection limit is an increasingly common and challenging problem in
biomarker studies. When a biomarker is used to predict survival outcome, one of the impor-
tant problems due to censored biomarker data is corrupted evaluation measures. Biomarker's
discrimination potential for survival outcome is frequently evaluated by C-index and time
dependent ROC curve. In this chapter, we extend these two methods to left-censored base-
line biomarker data. To incorporate the censored biomarker measurements, we use the joint
likelihood based method. We derive the analytic form of C-index and time dependent AUC,
which is a function of parameters in the joint likelihood function. Simulation study shows
that the proposed method outperforms over simple substitution methods in terms of param-
eter estimation, resulting in less biased evaluation measures. We provide the application
with the dataset from biomarker study for acute kidney injury patients.
5.1 INTRODUCTION
The ROC curve has been widely used in the evaluation of diagnostic accuracy for dichoto-
mous outcomes. In a prospective study when the disease onset is observed over a continuous
follow-up time, the essential outcome of interest is not only the occurrence of disease (bi-
nary) but also the time to event (continuous). In the context of survival outcome, it is more
appropriate to consider event time in the calculation of ROC curve. A common example
of the extended version of ROC curve to survival outcome is C-index, so called a global
accuracy summary measure. The C-index measures how well a biomarker correctly ranks
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patients by their survival time throughout the whole study period. When a priori time t is
specied, however, time-dependent ROC curve is more desired. The time-dependent ROC
curve summarizes the discriminant potential of a biomarker for cumulative events occurred
by time t. In this way, the ROC curve is expressed as a function of time. In the Biological
Markers of Recovery for the Kidney (BioMaRK) study, one of the scientic hypotheses is
that urinary biomarkers can predict the recovery outcome of renal function for critically ill
patients with acute kidney injury (AKI). It derives the consequent questions that (1) which
biomarker has the best discrimination ability for the time to recovery overall and (2) how
well the biomarker can distinguish patients who will recover with those who will not by the
follow-up time of t. The rst question can be answered by the C-index because scientic
interest is more on the biomarker's global discrimination ability for the whole study period.
Cumulative/dynamic ROC curve can be applied for the analysis of second question, which
focuses more on case or control group on the basis of their vital status at t.
The C-index and time dependent ROC curve have been successful evaluation methods for
survival outcome. The C-index and its property were studied by Harrell et al. [32], Pencina
and D'Agostino [34], and investigated further to obtain a stable estimation in the presence of
tied pairs or censoring in the survival outcome [35] [36]. Later, Gonen and Heller [76] derived
analytical expression of the concordance probability in the Cox proportional hazard model.
The standard ROC curve has been extended to time to event outcome by Heagerty et al. [39]
in the form of cumulative/dynamic time dependent ROC. They introduced a new denition
of sensitivity, specicity, and ROC curve in a time dependent manner. Chambless and
Diao [77] developed two dierent estimation method for time dependent AUC as a summary
measure of time dependent ROC. However, all of these methods have a limitation to be
directly applied to the BioMaRK study because they were developed based on fully detectable
data. In our application example, some of urinary biomarker measurements are not observed
due to detection of limit. To incorporate censored biomarker data as a covariate in the
analysis of survival outcome, D'Angelo et al. [78] presented an index approach in the Cox
proportional hazard model. When estimating model, they replaced the censored observations
with conditional expectation given fully observed covariates. In this chapter, we will propose
a modication of the C-index and time dependent ROC for censored biomarker data. We
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start from the joint likelihood based approach to analyze survival outcome in the presence
of censored covariate. We briey review the existing estimation methods for the C-index
and time dependent ROC and explain our remedy for censored biomarker measurements. In
section 5.3, we examine the performance of the proposed method using simulation study. In
section 5.4, the proposed methods are applied to the BioMaRK study in order to evaluate
the inammatory marker interleukin-6 (IL-6) and IL-18 in the prediction of time to recovery
outcome.
5.2 METHOD
5.2.1 Survival model with censored covariates
Survival data are commonly tted by a density function of parametric distribution or by a
semiparametric Cox proportional hazard model. While many researches have been done for
censored outcome, a model for both censored outcome and censored covariate has not been
extensively investigated yet. In this section, we consider the joint likelihood based approach
to handle the censored covariates in the survival model.
Parametric distribution of survival time
First, we assume the parametric form for the distribution of survival time. One of frequently
used distributions for survival time is exponential distribution, which has the constant haz-
ard during the whole study period. Denote by Zi the survival time for the i
th subject with
baseline biomarker value Yi (i = 1    N). The relationship between Yi and Zi is determined
through the exponential distribution function, h(zijyi) = iexp( izi), where i = exp(yi).
For each subject, what we actually observe for survival time is Ti = min(Zi, Ci), where Ci
represents a censoring time. Let i be the censoring indicator, i = 1 if the subject develops
an event within a study period, i.e. Ti = Zi, and i = 0 for the subject who is either loss of
follow up or event free at the end of a study, i.e. Ti = Ci. The baseline biomarker Yi has a
density function f(), which is often assumed to follow (log)normal distribution. We specify
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the censoring indicator for a biomarker with lower detection limit at  as follows.
!i =
8<: 1 if Yi  0 if Yi > 
To incorporate left censored biomarker data in the estimation of a set of parameters f, g,
we use the join likelihood based method, similar to Lyles et al.[19]. The likelihood function
for the observed data (t, , y)=(ti, i, yi, i = 1    N) is given by
L(; ; t; ; y) =
NY
i=1
ff(yi)h(tijyi)if1 H(tijyi)g1 ig1 !i (5.1)
f
Z 
 1
f(yi)h(tijyi)if1 H(tijyi)g1 idyig!i

; (5.2)
where H() denotes the cumulative distribution function for survival time.
Cox proportional hazard model of survival time
The parametric distribution for survival outcome is not always useful, especially in case of
survival time after a major surgery. Semiparametric methods are more appropriate in such
a situation. The Cox proportional hazard model has been the most widely used procedure
in biomedical survival analysis. We can generalize our survival model to Cox proportional
hazard model. The Cox proportional hazard model is dened as i(z) = 0(z)exp(yi),
where i() is the hazard function given yi, 0() is the baseline hazard function and  is
regression parameter. With left-censored covariates, the likelihood function is modied as
L(; ; t; ; y) =
NY
i=1

ff(yi) (0(ti)exp(yi))i exp

 
Z ti
0
0(u)exp(yi)du

g1 !i
 f
Z 
 1
f(yi) (0(ti)exp(yi))
i exp

 
Z ti
0
0(u)exp(yi)du

dyig!i

: (5.3)
Rather than specifying a certain distribution for the baseline hazard, we adopt the piecewise
constant baseline hazard function. We divide a follow-up period until last event into 20
intervals, which are found out to give stable parameter estimates in our simulation study.
The piecewise constant baseline is simple but powerful function in terms of exibility and
practical applicability. Another advantage of using it in the estimation process is that we
can avoid computational diculties by employing Gaussian quadrature techniques. It is
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pointed out that Gaussian quadrature technique for the Cox proportional hazard model
assuming piecewise constant baseline hazards yields satisfactory parameter estimates [79].
We implement the Gaussian quadrature technique using SAS Proc nlmixed procedure.
5.2.2 C-index
The C-index measures biomarker's discrimination ability for survival outcome over the whole
study period. Let's denote the actual survival time for ith subject as Zi, predicted survival
time as Ui, predicted probability of survival at time t as Wi, and time-invariant biomarker
measurement as Yi (i = 1    N). Harrell et al. [33] dened the C-index as Pr(Ui < UjjZi <
Zj), the probability that the person with a shorter event time has a shorter predicted survival
time assuming two persons are randomly selected from a cohort. It is pointed out that Ui
and Wi are exchangeable if they have one-to-one correspondence. Furthermore, under the
proportional hazards assumption, the C-index can be rewritten as Pr(Wi < WjjZi < Zj) =
Pr(Yi > YjjZi < Zj) [34].
There are two ways to estimate the C-index. Without a distributional assumption on
biomarker data, the C-index (Cn) is estimated by
C^n =
1
Q
X
(i;j)2R
cij;
where R is a set of all usable pairs, Q is the total number of usable pairs in R, and
cij =
8<: 1 if (Zi < Zj and Yi > Yj) or (Zi > Zj and Yi < Yj)0 if (Zi < Zj and Yi < Yj) or (Zi > Zj and Yi > Yj):
Alternately, distributional assumptions on biomarker data enable us to calculate the C-index.
Suppose g(z; y) denote the joint density function of actual survival time and biomarker.
For illustration, we assume that the subject with higher risk of event has larger biomarker
measurements, i.e.  > 0. Then the C-index can be calculated as
Cp = Pr(Yi > YjjZi < Zj) = Pr(Yi > Yj; Zi < Zj)
Pr(Zi < Zj)
=
R1
 1
R yi
 1
R1
0
R zj
0
g(zi; yi)g(zj; yj) dzidzjdyjdyiR1
 1
R1
 1
R1
0
R zj
0
g(zi; yi)g(zj; yj) dzidzjdyjdyi :
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Because we derive the C-index, Cp, directly from the joint likelihood function, it only depends
on the parameters in the distribution function. Therefore, Cp can be estimated correctly even
in the presence of censored covariates and censored outcomes if we can obtain the unbiased
parameter estimates.
Estimation under parametric distribution
Going back to the parametric distribution for survival data, we additionally assume that
biomarker Yi is independently, identically and normally distributed with mean  and vari-
ance 2. We can rewrite the joint density function g(z; y) as conditional density of survival
time, h(zjy), multiplied by the marginal density of biomarker, f(y). Then Cp is expressed
numerically by
Cp =
R1
 1
R yi
 1
R1
0
R zj
0
h(zijyi)h(zjjyj) f(yi)f(yj) dzidzjdyjdyiR1
 1
R1
 1
R1
0
R zj
0
h(zijyi)h(zjjyj)f(yi)f(yj) dzidzjdyjdyi
=
R1
 1
R yi
 1
R1
0
R zj
0
iexp( izi) jexp( jzj) exp

 (yi )2
22

exp

 (yj )2
22

dzidzjdyjdyiR1
 1
R1
 1
R1
0
R zj
0
iexp( iti) jexp( jtj) exp

 (yi )2
22

exp

 (yj )2
22

dzidzjdyjdyi
;
where , 2 and  are estimated by maximizing the joint likelihood function (5.1).
Estimation under Cox proportional hazard model
In the framework of Cox proportional hazard model and Yi  N(, 2), the C-index is for-
mulated even more simpler. Rather than starting directly from the joint distribution, we
express Cp in terms of Pr(Zi < ZjjYi = yi; Yj = yj) as follows :
Cp =
Pr(Yi > Yj; Zi < Zj)
Pr(Zi < Zj)
=
R1
 1
R yi
 1 Pr(Zi < Zjjyi; yj)f(yi)f(yj) dyjdyiR1
 1
R1
 1 Pr(Zi < Zjjyi; yj)f(yi)f(yj) dyjdyi :
Because
Pr(Zi < ZjjYi = yi; Yj = yj) =
Z 1
0
S(zjyi)dS(zjyj) = 1
1 + exp(yj   yi) ;
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where S(:) denotes a survival function, Cp can be calculated using only regression parameter
, distributional parameter  and 2 estimated from the joint likelihood function (5.3) [76].
The analytic form of Cp is given by
Cp =
R1
 1
R yi
 1 exp

 (yi )2
22

exp

 (yj )2
22

= (1 + exp(yj   yi)) dyjdyiR1
 1
R1
 1 exp

 (yi )2
22

exp

 (yj )2
22

= (1 + exp(yj   yi)) dyjdyi
:
5.2.3 Cumulative/dynamic time dependent ROC
If the biomarker's discriminant ability throughout the time interval (0, t] is of clinical in-
terest, cumulative/dynamic time dependent ROC can be used as a standard summary of
accuracy. If Y denotes the baseline biomarker measurement with higher value being more
indicative of event and Z is actual survival time, sensitivity and specicity are specied
as Sensitivity(t) = Pr(Y > cjZ  t) and Specificity(t) = Pr(Y  cjZ > t). In other
words, sensitivity is evaluated using events which occur in the time interval (0, t], whereas
specicity is calculated based on events after the time t. The AUC at time t is dened as
AUC(t) = Pr(Yi > YjjZi  t; Zj > t), the probability that subjects with an event by time t
has a higher biomarker level than those without an event.
Heagerty et al. [39] showed nonparametric estimation method for AUC(t) employing
the Kaplan-Meier estimator for survival function and empirical distribution function for
biomarker measurements. The estimator for sensitivity and specicity at time t is given by
Sensitivity(t) =
f1  S^(tjY > c)gf1  K^(c)g
1  S^(t)
Specificity(t) =
S^(tjY  c)K^(c)
S^(t) ;
where K^(c) =
NX
i=1
I(Yi  c)=N and S^(tjY  c) is the Kaplan-Meier estimator based on
the subset of subjects with fY  cg. Using the sensitivity(t) and specificity(t) over all
possible values of c, AUC can be estimated by the trapezoidal rule. As an alternative
estimation approach, Chambless and Diao [77] derived the direct formula for AUC(t) in
terms of a survival function and density function for biomarker. Denote the conditional
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density function of biomarker as q(yjz) and marginal density function of biomarker as f(y).
Then,
AUC(t) = Pr(Yi > YjjZi  t; Zj > t) =
Z 1
 1
Z 1
yj
q(yijZi  t)q(yjjZj > t) dyidyj:
Because
q(yijZi  t) = Pr(Zi  tjYi = yi)f(yi)
Pr(Zi  t) =
(1  S(tjyi))f(yi)R1
 1(1  S(tjyi))f(yi)dyi
=
(1  S(tjyi))f(yi)
E [(1  S(tjYi))] ;
where E indicates the expectation with respect to Yi. Therefore, the AUC(t) can be written
as Z 1
 1
Z 1
yj
(1  S(tjyi)) f(yi)S(tjyj)f(yj)dyidyj
E [1  S(tjYi)]E [S(tjYj)] =
E [(1  S(tjYi))S(tjYj)I(Yi > Yj)]
E [1  S(tjYi)]E [S(tjYj)] :
Estimation under parametric distribution
We rst assume the parametric distributions for both survival time and biomarker data
censored by a lower detection limit as follows.8<: Yi = + ei , ei  N(0; 2)ZijYi  EXP(i) ,where i = exp(Yi):
Under this assumption, the AUC(t) is given by
AUC(t) =
R1
 1
R1
yj
(1  exp( it)) exp( jt) exp

 (yi )2
22

exp

 (yj )2
22

dyidyjR1
 1
R1
 1 (1  exp( it)) exp( jt) exp

 (yi )2
22

exp

 (yj )2
22

dyidyj
;
where ^, ^2, ^i and ^j are maximum likelihood estimates obtained from (5.1).
Estimation under Cox proportional hazard model
Everything being same as before, we use the Cox proportional hazard model i(z) =
0(z)exp(yi) for survival outcome. In this case, the survival function at time z is specied as
S(zjyi) = S0(z)exp(yi), where baseline survival function S0(z) is given by exp( 
R z
0
0(u)du).
The C-index depends only on the regression coecient  in the Cox proportional hazard
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model, so the estimation of baseline hazard is unnecessary. However, we cannot estimate
AUC(t) without obtaining baseline hazard function. In the semiparametric model, the base-
line hazard is usually unspecied and it can have any form. By assuming the piecewise
constant hazard, however, we can circumvent this problem. Suppose we divide the follow-up
period into 20 intervals and denote Ik (k=1,   ,20) as every 5th quantile. The 0k is the
piecewise constant baseline hazard in each interval, i.e. 0(t) = 0k for [Ik 1 < t  Ik].
Then, the cumulative baseline hazard is [79]
Z t
0
0(u)du =
20X
k=1
0k max (0; min (Ik   Ik 1; t  Ik 1)):
Now the AUC(t) can be obtained by using the parameter estimates from the likelihood
function (5.3) and the estimate of cumulative baseline hazard,
AUC(t) =
R1
 1
R1
yj
 
1  S0(t)exp(yi)

S0(t)
exp(yj) exp

 (yi )2
22

exp

 (yj )2
22

dyidyjR1
 1
R1
 1 (1  S0(t)exp(yi)) S0(t)exp(yj) exp

 (yi )2
22

exp

 (yj )2
22

dyidyj
:
5.3 SIMULATION
In the rst simulation, we present the point estimates of C-index calculated from the pro-
posed method as well as those from the substitution methods, in which censored biomarker
measurements are replaced by LOD and LOD/2. True value of the C-index is obtained from a
numerical integration using the known parameter values. For data generation, time-invariant
biomarker measurements are simulated from Y  N(; 2). The actual survival time Z is
assumed to follow the exponential distribution ZjY  EXP (), where  = exp(0 + 1y).
We simulate censoring time C from the uniform distribution U(0, 4) and take the observed
time as T=min(Z, C). The C-index is expected to be larger when biomarker data are widely
distributed so that biomarker level from a subject with shorter survival time shows big dif-
ference from that from a subject who lives longer. Correspondingly, the variability of Y , 2,
is varied at the level of 0.1, 1.0, and 5.0. Other parameters are xed at =0.0, 0=0.0 and
1=1.0. Under this setup, a subject with higher biomarker value has higher risk of event.
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The lower detection limit for biomarker Y is chosen empirically so that the censoring rate
is set to 0.2 and 0.4. Total 500 observations are generated for each dataset. For evaluation,
estimated C-indices and parameter estimates are averaged over 100 datasets. Later, we gen-
eralize the distributional assumption for survival time and use the Cox proportional hazard
model. Fixing other simulation setup the same as before, we regenerate the actual survival
time Z based on the hazard function (z) = 0(z)exp(y), where 0(z) = 2z and =1.
Tables 8 and 9 summarize the simulation results under the assumption of exponential
distribution and Cox proportional hazard model, respectively. The parameter estimates from
the proposed method are close to the true values, while larger biases are shown in the sub-
stitution methods as censoring proportion becomes higher. The C-index from substitution
methods tends to be biased downward. Our method produces C-index that is much closer
to the true value, which is competently similar to the omniscient estimate obtained from
complete data.
The second part of the simulation study is designed to compare the performance of our
method in estimating AUC(t) to that of the substitution methods. In this simulation, base-
line biomarker measurements are generated from Y  N(; 2) with  = 0 and 2 = 4 and 9.
We simulate actual survival time Z from exponential distribution, EXP [exp(0+1y)] with
0 = 0 and 1 = 0.1. The censoring time C follows uniform distribution U(0, 4). For the Cox
proportional hazard model, we generate the actual survival time Z with exponential survival
for S0(Z) and 1 = 0.1. Tables 10 and 11 present the results averaged over 100 datasets. The
simulation results show that the proposed method produces comparable AUC(t) estimates
to omniscient and true values. However, the biases of both parameter and AUC(t) estimates
from the substitution methods increase with the censoring proportion.
5.4 APPLICATION TO BIOMARK STUDY
Acute kidney injury (AKI) is the most common problem in the intensive care unit, which
aects negatively on patient's quality of life and causes subsequent health care cost [80].
Conducted as a part of the Acute Renal Failure Trial Network study (ATN study), the
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Table 8: Comparison of C-index estimated from the proposed method (PM) and substitution
methods (LOD, LOD/2) assuming exponential distribution for survival time ( = 0, 0 =
0, 1 = 1)
2 Pr(censor) Method ^ ^2 ^0 ^1 C C^(SD)
0.1 0.2 Omni -0.001 0.100 0.004 1.017 0.586 0.588(0.015)
LOD 0.034 0.069 -0.037 1.167 0.584(0.014)
LOD/2 0.061 0.056 -0.073 1.236 0.580(0.013)
PM 0.001 0.098 0.002 1.032 0.588(0.014)
0.4 Omni -0.001 0.100 0.004 1.017 0.586 0.588(0.015)
LOD 0.089 0.044 -0.118 1.349 0.578(0.014)
LOD/2 0.105 0.040 -0.146 1.399 0.577(0.013)
PM 0.004 0.097 0.000 1.039 0.588(0.014)
1.0 0.2 Omni -0.004 1.004 0.007 1.004 0.725 0.726(0.010)
LOD 0.108 0.695 -0.090 1.110 0.713(0.009)
LOD/2 0.193 0.561 -0.200 1.184 0.707(0.009)
PM -0.001 0.994 0.006 1.008 0.725(0.010)
0.4 Omni -0.004 1.004 0.007 1.004 0.725 0.726(0.010)
LOD 0.281 0.448 -0.329 1.282 0.702(0.010)
LOD/2 0.333 0.396 -0.415 1.333 0.699(0.010)
PM 0.001 0.993 0.004 1.009 0.725(0.010)
5.0 0.2 Omni -0.009 5.020 0.003 1.003 0.801 0.800(0.004)
LOD 0.243 3.481 -0.096 1.050 0.801(0.003)
LOD/2 0.432 2.809 -0.277 1.112 0.799(0.003)
PM -0.005 4.990 0.002 1.004 0.800(0.004)
0.4 Omni -0.009 5.020 0.003 1.003 0.801 0.800(0.004)
LOD 0.628 2.239 -0.510 1.188 0.795(0.004)
LOD/2 0.745 1.977 -0.684 1.235 0.793(0.004)
PM -0.007 5.006 0.002 1.004 0.800(0.004)
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Table 9: Comparison of C-index estimated from the proposed method (PM) and substitution
methods (LOD, LOD/2) assuming Cox proportional hazard model for survival time ( = 0,
 = 1)
2 Pr(censor) Method ^ ^2 ^ C C^(SD)
0.1 0.2 Omni -0.001 0.100 0.993 0.586 0.586(0.013)
LOD 0.034 0.069 1.143 0.582(0.013)
LOD/2 0.061 0.056 1.208 0.578(0.013)
PM 0.001 0.099 1.003 0.586(0.014)
0.4 Omni -0.001 0.100 0.993 0.586 0.586(0.013)
LOD 0.089 0.045 1.326 0.577(0.013)
LOD/2 0.105 0.040 1.374 0.575(0.012)
PM 0.004 0.097 1.016 0.586(0.014)
1.0 0.2 Omni -0.004 1.004 1.007 0.725 0.726(0.011)
LOD 0.108 0.695 1.118 0.714(0.011)
LOD/2 0.193 0.561 1.165 0.704(0.011)
PM -0.001 0.994 1.010 0.726(0.012)
0.4 Omni -0.004 1.004 1.007 0.725 0.726(0.011)
LOD 0.281 0.448 1.263 0.700(0.011)
LOD/2 0.333 0.396 1.300 0.695(0.011)
PM 0.001 0.992 1.012 0.726(0.012)
5.0 0.2 Omni -0.009 5.020 1.008 0.843 0.844(0.008)
LOD 0.243 3.475 1.081 0.829(0.008)
LOD/2 0.432 2.809 1.111 0.818(0.008)
PM -0.005 4.989 1.004 0.843(0.008)
0.4 Omni -0.009 5.020 1.003 0.843 0.844(0.008)
LOD 0.628 2.239 1.188 0.812(0.009)
LOD/2 0.745 1.977 1.235 0.807(0.009)
PM -0.007 5.006 1.004 0.843(0.008)
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Table 10: Comparison of AUC(t) estimated from the proposed method (PM) and substitu-
tion methods (LOD, LOD/2) assuming exponential distribution for survival time
Pr(censor) Method ^ ^2 ^0 ^1 dAUC(3)(SD) dAUC(5)(SD)
True 0.000 4.000 0.000 0.100 0.663 0.737
0.2 Omni -0.005 4.001 0.018 0.102 0.665(0.037) 0.738(0.044)
LOD 0.218 2.770 -0.010 0.119 0.661(0.037) 0.732(0.045)
LOD/2 0.386 2.239 -0.033 0.127 0.656(0.038) 0.726(0.048)
PM -0.002 3.971 0.016 0.103 0.665(0.037) 0.738(0.045)
0.4 Omni -0.005 4.001 0.018 0.102 0.665(0.037) 0.738(0.044)
LOD 0.564 1.779 -0.063 0.140 0.653(0.040) 0.723(0.050)
LOD/2 0.667 1.573 -0.082 0.146 0.650(0.040) 0.719(0.050)
PM 0.003 3.955 0.016 0.104 0.667(0.039) 0.740(0.046)
True 0.000 9.000 0.000 0.100 0.727 0.803
0.2 Omni -0.009 9.003 0.015 0.102 0.726(0.029) 0.805(0.029)
LOD 0.327 6.233 -0.024 0.117 0.719(0.030) 0.798(0.031)
LOD/2 0.582 5.041 -0.058 0.125 0.713(0.032) 0.791(0.034)
PM -0.004 8.943 0.015 0.102 0.726(0.030) 0.804(0.030)
0.4 Omni -0.009 9.003 0.015 0.102 0.726(0.029) 0.805(0.029)
LOD 0.848 4.010 -0.104 0.137 0.709(0.033) 0.787(0.034)
LOD/2 0.999 3.539 -0.129 0.143 0.705(0.033) 0.784(0.036)
PM 0.001 8.917 0.015 0.103 0.727(0.032) 0.805(0.032)
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Table 11: Comparison of AUC(t) estimated from the proposed method (PM) and substitu-
tion methods (LOD, LOD/2) assuming Cox proportional hazard model for survival time
Pr(censor) Method ^ ^2 ^ dAUC(1)(SD) dAUC(2)(SD)
True 0.000 4.000 0.100 0.588 0.624
0.2 Omni -0.008 4.017 0.098 0.586(0.023) 0.620(0.031)
LOD 0.217 2.780 0.113 0.583(0.023) 0.617(0.031)
LOD/2 0.386 2.247 0.119 0.580(0.023) 0.613(0.031)
PM -0.004 3.988 0.099 0.587(0.024) 0.623(0.034)
0.4 Omni -0.008 4.017 0.098 0.586(0.023) 0.620(0.031)
LOD 0.562 1.791 0.132 0.580(0.023) 0.614(0.023)
LOD/2 0.666 1.581 0.136 0.578(0.022) 0.612(0.031)
PM -0.003 3.987 0.100 0.587(0.025) 0.623(0.034)
True 0.000 9.000 0.100 0.629 0.677
0.2 Omni -0.012 9.037 0.099 0.627(0.023) 0.672(0.028)
LOD 0.325 6.254 0.113 0.623(0.023) 0.668(0.028)
LOD/2 0.579 5.055 0.119 0.618(0.023) 0.664(0.029)
PM -0.007 8.983 0.100 0.628(0.023) 0.675(0.030)
0.4 Omni -0.012 9.037 0.099 0.627(0.023) 0.672(0.028)
LOD 0.842 4.030 0.131 0.618(0.023) 0.665(0.030)
LOD/2 0.999 3.558 0.134 0.615(0.025) 0.662(0.034)
PM -0.007 8.987 0.100 0.628(0.024) 0.675(0.031)
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Biological Markers of Recovery for the Kidney (BioMARK) study is designed to investigate
the role of plasma and urinary biomarkers in prediction of renal outcomes. The objective of
our analysis is to measure the biomarker's predictive accuracy for time to recover of renal
function. Furthermore, we investigate the biomarker's discrimination power for cumulative
recovery events by time t. The baseline urine biomarkers were collected from 76 participants
in the intensive monitoring cohort. We select IL-6 and IL-18 as biomarkers of interest for
the illustration purpose of our method. The censoring proportions for the baseline IL-6 and
IL-18 are 14.9% and 15.5%, respectively. Recovery of renal function is dened by survival
and dialysis independence. For this analysis, all deaths are treated as censored at the end
of the follow-up, 60 days. Total 53% subjects have censored survival outcome.
We assume the log-normal distribution for baseline biomarker measurements and use the
Cox proportional hazard model for time to recover data. The estimated value of the C-index
for IL-6 is 0.579. The LOD and LOD/2 substitutions produce the C-indices of 0.570 and
0.575. As expected, the substitution methods report lower discrimination power for time to
recovery. For IL-18, we calculate AUC(t) at t=20 and t=40. The discrimination potential
for IL-18 is pretty low; 0.508 at 20 days and 0.509 at 40 days. The AUC(t) from substitution
method (LOD/2) is 0.501 for both time points.
5.5 DISCUSSION
In this chapter, we extend the C-index and time dependent ROC methods to time-invariant
censored biomarker data. In the estimation procedure, both methods require to t a survival
model including biomarker measurements as a covariate. In order to reduce a bias caused
by censored covariates in the survival model, we use joint likelihood approach. The simula-
tion study shows that our approach provides improved estimates than the LOD or LOD/2
substitution methods for the considered scenarios. Better parameter estimation enables us
to calculate the C-index and time dependent AUC correctly because those measures depend
on the parameters in the joint likelihood function.
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In the survival analysis, all the subjects in the cohort are followed in a given study
period. At the end of the study, subject can have an event of interest, does not experience
an event, or can be lost during the follow-up without an event. The proposed estimation
method considers all of these cases in the model. Thus C-index and time-dependent AUC
are not sensitively aected by censoring proportion of survival outcome.
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6.0 CONCLUSION
The main objective of this dissertation is to develop discriminant models and corresponding
evaluation methods for censored biomarker data when the outcome is either binary or time
to event data. For the binary outcome, we propose a new discriminant analysis method.
We use the likelihood based method to account for the censoring due to detection limit.
The classication is based on the newly calculated risk scores that are derived using a linear
mixed model. Through the simulation, we point out that the linear mixed model should
be carefully specied by comparing t statistics. The discrimination power is evaluated by
AUC. Furthermore, we assess the biomarker's predictive capacity by predictiveness curve.
As an alternative classication method, joint modeling approach is desirable. The ba-
sic idea under the joint modeling is that the linear mixed model for censored longitudinal
biomarker data and logistic regression model for binary outcome can be linked via shared
random eect parameters. In this case, posterior probability of event takes a role of the
risk score from our discriminant analysis. Patients can be classied into two groups based
on the the posterior probability. One of the diculties in this approach is the estimation
of individual's random eects, which are not actually observed. Further research should be
carried out to calculate individual's posterior probability which is a function of random eect
parameters.
Regarding the evaluation of biomarker performance, we investigate the AUC calculation
for biomarkers with large time dimensions. Rather than directly handling longitudinal data,
some researchers want to use condensed measure which contains all the information in the
longitudinal data. We derive the best linear combination of time points that maximizes the
AUC for both censored and non-censored biomarkers. Our methodology is easy and straight-
forward to implement with standard statistical software and provides satisfactory evaluation
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results. Although we introduce the optimum AUC for single longitudinal biomarker here,
the extension to the multiple longitudinal biomarkers would be possible.
For the survival outcome, we develop two evaluation methods for time-invariant censored
biomarker data. Previous studies have introduced the new denition of sensitivity and
specicity so that a biomarker's performance can be evaluated in a time dependent manner.
In case a priori time point is not specied for evaluation, a global summary measure of
discrimination can be used. Based on these concepts, we develop the estimation methods
for a time dependent AUC and C-index by using a joint likelihood function of time to event
and censored biomarker data. The time to event data are tted by either parametric model
or semi-parametric Cox proportional hazard model.
All the proposed methods are based on the assumption of normal distribution. However,
the biomarker data are often highly skewed and may not satisfy the normality assumption.
Appropriate treatment such as Box-Cox transformation can be considered to make the dis-
tribution of data close to normal. We mainly use the likelihood-based method to handle the
censored data. As an alternative, multiple imputation method is increasingly applied to the
analysis of censored data. Once the data set is completed by the imputed values, we can
utilize the evaluation methods for biomarker which have been developed for fully observed
data.
Our methodology can be widely applied to clinical decision-making when it is necessary
to handle below or above the detection limit values. The proposed methods are useful to
improve the quality of clinical decision making and facilitate health policy formation so that
patients can get better treatment with less health care cost.
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